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Abstract 
Regenerative medicine is an emerging field that aims to treat injury and disease by harnessing and 
augmenting the body’s innate capacity for tissue regeneration. Many of the strategies developed in 
this field have relied extensively on the principles of tissue engineering, a set of methods that bring 
together cells, cellular signals and material scaffolds to repair or replace biological tissue. While the 
number of novel tissue engineering strategies continues to rapidly expand, the innovations underlying 
these solutions often fail to consider the key technical, manufacturing, and regulatory barriers that 
prohibit these technologies from suitable use in humans. As a result, the field of tissue engineering 
has one of the lowest rates of clinical translation amongst medical research. To address this, this thesis 
examines each of the prominent components of the tissue engineering practice and develops tools and 
strategies that enable the development of solutions with high translational potential.  
First, using well characterised electrospun polycaprolactone (PCL) scaffolds as an exemplar material, 
we develop a novel imaging method that allows monitoring of scaffold performance non-invasively 
and in real-time. Based on bioluminescence imaging, this tool allows us to determine how injected 
stem cell populations interact with scaffolds after they have been implanted, while also providing an 
assessment of the functional regenerative outcomes. These findings provide an advantageous new 
tool for the tissue engineering community that eliminates current trial-and-error methodology, with 
potential to drastically improve the time and cost constraints of current scaffold design and 
innovation. 
Secondly, using these imaging modalities, we examine some of the unknown effects of novel stem 
cell sources. Tracking the engraftment behaviour of induced-pluripotent stem cell derived endothelial 
cells (iPSC-ECs), we demonstrate for the first time that this stem cell phenotype possesses 
therapeutically relevant tissue regenerative properties, and the extent of these functions are associated 
with their engraftment behaviour. These findings add fundamental knowledge to the understanding 
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of iPSCs by highlighting the tissue regenerative capacity of iPSC-ECs, with broader implications for 
advancing the field of iPSC biology by potentially spurring the investigation of other iPSC lineages 
for tissue regenerative potential.  
Thirdly, to enhance the translation of iPSC-EC therapy as a clinically relevant regenerative medicine 
approach, we combined them with tissue engineered scaffolds. We fabricated an array of electrospun 
PCL composite scaffolds containing gelatin blends, and using bioluminescence imaging, to rapidly 
identify a candidate scaffold which extends iPSC-EC engraftment and function in vivo. The findings 
of this study demonstrate a novel tissue engineering construct capable of tissue revascularisation, 
demonstrating one of the fundamental mechanisms of tissue regeneration as well as overcoming one 
the largest challenges of translating tissue engineering solutions. 
Lastly, we further emphasize the theme of translation by investigating acellular PCL scaffolds and 
biofunctionalisation.  For the first time, we examine the time and cost-effective plasma surface 
activation treatment on PCL scaffolds by immobilising the M2 macrophage polarising cytokine IL-
4. In this study we show that bioactive coatings of immobilised IL-4 significantly limited the foreign 
body response and improved the functional performance of implanted scaffolds including vascular 
grafts. The findings of this study demonstrate a novel off-the-shelf functionalisation method that 
improves host integration of acellular scaffolds by harnessing the inflammatory influence of 
macrophage polarisation. These bioactive coatings may have potential applications on a wide range 
of polymer-based tissue engineering scaffolds, improving both their long-term performance, 
integration, and clinical translational. 
The collective findings of these works propose tools and solutions applicable within the major facets 
of tissue engineering that may help to lay the groundwork for future therapies with high clinical 
probability in a number of regenerative medicine applications.  
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Thesis Presentation 
This thesis is presented as 4 published/submitted research manuscripts. Each manuscript describes 
the methods, results and discussion of the four major projects undertaken in this PhD candidature. 
Chapter 1 provides a general introduction to the field of regenerative medicine, tissue engineering 
and the challenges the lay in the path towards clinically translatable therapy, addressed by the main 
thesis chapters/research articles in Chapters 2-5 where the candidate is the principal author. A general 
discussion and conclusion about the findings and broader implications of these articles to the field is 
presented in Chapter 6 
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1. Introduction 
1.1. Regenerative Medicine 
One of the fastest growing biomedical practices in the world is regenerative medicine, an emerging 
field of medical science that aims to treat injury and disease by harnessing the body’s capacity for 
regeneration 1. In cases where the body cannot heal itself, this also includes the possibility of utilizing 
facilities and methods to grow tissue and organs outside the body for implantation 2. The numerous 
studies within this field encompass a large body of work that focuses on the replacment or 
regeneration of human cells, tissues and organs to restore normal function. While there are many 
biomedical approaches currently being explored, these strategies often rely on the use of stem cells 
as the key cellular components that facilitate functional repair. Currently, stem cells and their 
numerous differentiated lineages are being exploited therapeutically for a number of mechanistic 
approaches including: 1) cell therapy, involving direct injection into injured and/or diseased tissue 3 
2) immunomodulation therapy, where biologically active molecules secreted by stem cells are used 
to enhance tissue regeneration 4 and 3) tissue engineering, where stem cells are used as building 
blocks to grow/engineer organs and tissues ex vivo in combination with biomaterials for 
transplantation 5 (Figure 1). While the use and function of stem cells continue to be essential to 
regenerative medicine, the future development of therapies that may ultimately reach patients relies 
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on a deeper understanding of the mechanisms which regulate their stimulation, enhancement, and/or 
replacement of the human body’s innate tissue regenerative capabilities.  
 
Figure 1 – Stem Cells in Regenerative Medicine 
The contribution of stem cells towards the goals of regenerative medicine involve three main 
pathways. Stems are currently used as direct injection therapies to alleviate and cure symptoms 
within injured/disease organs and tissue. Their secreted factors are also isolated and used to 
influence the body’s innate capacity for tissue regeneration. In combination with material scaffolds, 
tissue engineered constructs can potentially replace whole tissue, restoring loss of organ function.  
1.1.1. Innate healing/tissue regenerative mechanisms 
Inadequate tissue regeneration following traumatic injury, acute illness, or chronic disease affects 
millions of people worldwide every year 6. This deficit is the consequence of dysfunctional elements 
of the normal tissue repair response, which include inflammation, angiogenesis, matrix deposition 
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and cell recruitment. Although underlying medical conditions such as vascular disease and diabetes 
are linked to the aggravated dysfunction of these elements, the human body’s natural capacity for 
regeneration is also inherently limited. Typically, the body’s response following injury involves the 
formation of scar tissue, rather than fully regenerating the organ back to its original state, with the 
exception of a few tissues such as the liver and endometrium 7, 8. However, advances in research are 
studying the various elements of innate tissue repair and have enabled the development of 
breakthrough strategies capable of induced regeneration of many more tissues and organs than 
originally thought possible. Below, we examine each of the key processes of tissue regeneration in 
detail (Figure 2). 
1.1.1.1. Inflammation 
Inflammation is the most crucial biological process of regeneration as it not only initiates but is 
actively involved in all stages of tissue repair. As a by-product of injured tissue, dying cells release 
various inflammatory mediators that exist to protect the body by eliminating or sequestering 
degenerative stimuli. These can include damage associated molecular patterns (DAMPs) 9, lipid 
mediators 10, oxygen and nitrogen radicals 11, chemokines and cytokines 12 which work in concert to 
trigger a local inflammatory response by recruiting inflammatory cells of the innate immune system 
through the circulation. This can occur as a single event such as immediately following a traumatic 
injury or a gradual release over a period of time from chronically diseased tissue.  
In most tissue, subsets of leukocytes, a white blood cell group evolved to protect the body from both 
infectious disease and foreign pathogens, are the predominant first responders migrating to sites of 
inflammation 13. These leukocytes include cells such as neutrophils, monocytes, and monocyte-
derived macrophages. Endowed with potent phagocytic and antimicrobial abilities which allow them 
to appropriately dispense of the inciting stimuli, these cells also actively participate in the controlled 
degeneration of injured tissue through the sustained and localised secretion of inflammatory 
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mediators, including matrix metalloproteinases (MMPs) 13. In healthy tissue, the continued 
recruitment of immune cells will eventually lead to elimination of the initiating stimulus, appropriate 
destruction and remodelling of the injured tissue, and finally inflammatory resolution.  
The resolution of inflammation is a highly coordinated process controlled by many distinct 
mechanisms. While it is known that the production of many pro-inflammatory cytokines is transient 
and the half-life of the mRNAs encoding these cytokines are generally short, it is becoming 
increasingly accepted that depletion of pro-inflammatory mediators alone is insufficient to halt 
inflammation 14. Equally important, the removal of leukocytes and their secretion products is also 
required. The primary mechanism controlling the local elimination of immune cells is through 
programmed apoptosis and subsequent removal via macrophage phagocytosis. This process 
stimulates macrophage release of cytokines such as transforming growth factor-β (TGF-β) and 
interleukin-10 (IL-10), which contribute to the resolution of inflammation by triggering further 
leukocyte apoptosis, while also stimulating the next stages of healing, angiogenesis and tissue 
remodelling 13.  
When these immunomodulatory feedback processes are intact, inflammation is self-restricting, and 
the inflammatory process yields no unnecessary tissue damage. Dysfunction of these resolution 
mechanisms leads to states of chronic inflammation and consequent tissue injury. Contributing 
factors to persistent immune responses include inefficient revascularisation processes and 
subsequently inadequate recruitment of stem and progenitor cells to rebuild tissue. Numerous chronic 
inflammatory disorders including rheumatoid arthritis, inflammatory bowel disease, type I diabetes, 
and even atherosclerosis are currently being addressed through regenerative medicine approaches 15. 
These strategies aim to replace the body’s loss functions of immune resolution allowing for the next 
stages of repair to occur. Many of these approaches are based on anti-inflammatory drugs. Although 
inflammation is not as prominent during the late stages of repair, numerous studies suggest that the 
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events during the inflammatory stage have drastic impacts on the ensuing tissue remodelling phases 
and ultimately the final regenerative outcome of the injured tissue 13.  
1.1.1.2. Revascularisation 
In forms of tissue injury where blood vessel walls are damaged, blood loss is initially curtailed by the 
formation of a haemostatic plug. Collagen fibers exposed in the damaged vessel wall adhere platelets 
in the blood stream 16. As platelets attach to the injured vessel, they rapidly upregulate binding 
integrins that mediate further platelet aggregation forming the haemostatic plug. After binding, 
platelets activate and degranulate, stimulating the release of procoagulant factors that trigger the 
formation of a fibrin clot to prevent further blood loss. Platelet degranulation also results in the release 
of signalling factors such as TGF-β and vascular endothelial growth factor (VEGF) which contribute 
to the chemoattractant gradient within the tissue injury that is responsible for the recruitment of 
inflammatory and reparative cells 17. In doing so, endogenous revascularisation mechanisms are 
activated which are tasked with the establishing the local vascular network from the injured pre-
existing vasculature.  
Endothelial cells that line the inner surface of local blood vessels are activated by low oxygen/hypoxic 
conditions resulting from injury as well as increases in local secretion of pro-angiogenic factors from 
platelets and macrophages, including VEGF. In response, endothelial cells degrade their surrounding 
extracellular matrix and begin migrating and proliferating, and re-establishing cell-cell contacts 
forming new capillaries. An additional and more profound form of tissue revascularisation is 
vasculogenesis, which relies on the mobilisation of endothelial progenitor cells (EPCs) from the bone 
marrow to form large diameter arterioles 18. Over time, the overabundance of newly formed 
capillaries and arterioles regress, resulting in a normal vascular density. 
Angiogenesis is an indispensable process to tissue regeneration and is reliant on several facets of the 
regenerative process 18. Macrophages, fibroblasts and new blood vessels simultaneously invade the 
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injured tissue as a unit and exhibit high interdependence. Macrophages provide a continuing source 
of pro-angiogenic factors while also releasing cytokines that stimulate fibroblast migration and 
deposition of new extracellular matrix required for cell ingrowth 13. Cells repopulating injured tissue 
are inherently dependent on their local vasculature to supply critical nutrients and remove waste 
products. It is generally accepted that impaired wound revascularisation can impede healing as 
inadequate blood perfusion is often a hallmark of chronic wounds. Current regenerative medicine 
approaches to address tissue revascularisation have spurred a research field known as therapeutic 
angiogenesis that aims to augment the body’s innate angiogenesis mechanisms during tissue repair 
19. However, the cellular events required for angiogenesis are often not readily addressed through the 
administration of single factors alone 19, but rather involve a highly dynamic and complex interaction 
between endothelial cells, immune cells, and, perhaps more importantly, the surrounding tissue 
environment consisting of a highly dynamic turnover of extracellular matrix proteins.   
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Figure 2 – Stages of Wound Healing 
Three major stages of wound healing involve inflammation, revascularisation, and tissue 
remodelling. Immune cells invade the wound bed to clear necrotic tissue and cells, allowing wound 
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regeneration responses to occur. These include angiogenesis to re-establish the vasculature which 
leads to the migration of tissue remodelling cells to close the wound. 
1.1.1.3. Tissue remodelling 
The last stages of tissue regeneration predominantly involve remodelling of the extracellular matrix. 
This process requires an intricate balance of matrix protein synthesis and degradation. Some of the 
key mediators in this process are MMPs and their inhibitors, tissue inhibitors of metalloproteinases 
(TIMPs) 20. During the peak of the inflammatory phase, leukocytes facilitate the removal of damaged 
matrix proteins through the release of tissue-specific MMPs. Amongst the numerous mediators 
released by macrophages during immune resolution, TIMPs are essential to halt MMP degradation 
and stimulate the infiltration and function of fibroblasts 20. The primary role of fibroblasts, regulated 
by macrophage secreted molecules such as fibroblast growth factor-2 (FGF-2), are to synthesize new 
extracellular matrix and collagen. Its initial role in tissue injury is to facilitate the formation of 
granulation tissue, a provisional matrix through which angiogenesis can occur and provide temporary 
structural support for the ingrowth and differentiation of new cells 21. Following closure of the wound, 
the fibers of the provisional matrix are realigned and cross-linked. The process of collagen alignment 
differentiates remodelled tissue following injury from normal healthy tissue, which consists primarily 
of randomised collagen fibers. Remodelled tissued often also confers inferior functional quality to 
healthy tissue and visually appears as what we know as scar tissue 22.  
Within most human organs, the natural regenerative outcome to injury or disease is some degree of 
scar tissue formation, also known as fibrosis. Fibrotic scar tissue is excess fibrous connective tissue 
comprised of the same protein (usually collagen) as the tissue it replaces. The increased speed at 
which scar tissue formation occurs in relation to complete tissue regeneration has, evolutionarily, 
been the reason why the body’s regenerative capacities are naturally limited 23.  The body’s initial 
response favours isolation/sealing of the injury site from the outside environment and possible 
infection, and this occurs at the expense of optimal tissue regeneration. As such, fibrosis negatively 
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affects organs and tissues by masking their underlying architecture and function. The consequence of 
all traumatic injury and organ failure is the presence of scar tissue. Restoration of functional ability 
to a tissue or organ is often determined by tipping the balance in favour of tissue regeneration over 
scar tissue formation.  
Regenerative medicine aims to assist in this endeavour through approaches that include favourable 
manipulation of innate healing responses and/or augmentation of tissue regenerative mechanisms. 
Often found at the centre of these research efforts is a vast range of stem cell applications. Stem cells 
or their secreted products are being trialled as direct injections and cell therapies for numerous 
diseases such as stroke 24, heart attack 25, diabetes 26, and neurodegeneration 27. Intensive research 
focus is also on the study of stem cell behaviour and function during foetal development, as tissue 
regeneration has been observed to be more prominent than fibrosis in the foetuses of humans and 
many other species. It is becoming increasingly apparent that stem cell function, origin, and 
application will become vital to the development of the next generation of regenerative medicine 
solutions. 
1.1.2. Stem Cells 
Following the first reporting of stem cell isolations in the early 1960s 28, it was not long before interest 
into their regenerative functions would emerge. Today this interest dominates current tissue 
regeneration strategies as aging and disease are linked to reduced regenerative capacity and 
dysfunction of endogenous stem cell reserves 29-31. This has highlighted them as a primary focus of 
many regenerative medicine applications and, given their extensive ability to self-renew and generate 
numerous cell lineages, they are continually under invesigation for their broad therapeutic potential. 
The most common therapeutic treatments involve transplanting patients with their own stem cells or 
stem cell-differentiated lineages. It has been long believed that stem cells for transplantation could be 
harvested only from accessible tissues such as the blood or skin. However, recent advances allow 
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directed stem cell differentiation into inaccessible or rare cell types that potentially can replace any 
cell in the body 28. From this technology, alternative methods to cell transplantation have been 
developed that attempt to manipulate stem cell behaviour and function in vivo. Despite the enormous 
potential underlying stem cell research, the development of clinical therapies since their discovery 
has been limited by controversy surrounding their origins and lack of consensus on the methods to 
control their behaviour in vivo 28. Adding to these challenges are the difficulties of stem-cell isolation 
and expansion due to their extensive heterogeneity. Marker-based identification of stem cells is often 
complicated by the changing nature of their surface markers. Numerous stem cell populations have 
been shown to maintain stem cell-like properties long after losing marker expression. Complicating 
this further is the severity of the disease, associated pre-existing conditions, and age which can not 
only alter the expression of stem cell surface markers, but also drastically impact the overall number 
of stem cells expressing a particular marker. This has made sourcing the appropriate stem cell 
population in adequate numbers elusive. To date, three main sources of stem cells each with varying 
levels of potency, meaning their potential to divide into numerous cell lineages, have been identified 
and are largely debated on which are the most suitable for regenerative therapy. 
1.1.2.1. Stem cell sources and potency 
1.1.1.1.1 Adult stem cells 
Adult stem cells, or resident stem cells, are undifferentiated cells found in adult tissue throughout life 
and are responsible for every day tissue maintenance (Figure 3). These cells are largely present in 
tissue that have rapid turnover rates such as bone marrow/blood, skin, and gut 32. Since these cells are 
native to individual tissues they are often characterised as having multipotency, meaning they give 
rise to multiple cells types of only a single organ. Adult stem cells divide asymmetrically, meaning 
they divide into a single stem cell to maintain their numbers while also giving rise to a cell of 
committed lineage. However, the renewal capacity of adult stem cells is limited and decreases with 
aging. In general, adult stem cells are required to divide quite rarely, however under the appropriate 
12 
 
stimulus, such as an increased demand for cells in regeneration of tissue injury, they are capable of 
readily proliferating and differentiating. Two common examples are epidermal stem cells in 
regenerating skin wounds 23 or the release of haematopoietic stem cells from the bone marrow into 
the blood when inflammation is activated 33.  Since adult stem cells are functioning components of 
the body’s innate mechanisms of healing, regenerative medicine approaches have been designed to 
manipulate their behaviour both in vivo for in situ regeneration 34 and in vitro for transplantation 35. 
Minimal cell numbers resident within adult tissue have been the primary barrier to these approaches 
as large cell amounts are often needed to therapeutically enhance native repair mechanisms. This need 
has spurred the advent of other stem cell sources possessing higher proliferative capacities, the first 
discovered being embryonic stem cells.  
1.1.2.1.1. Embryonic stem cells 
Embryonic stem cells are derived in culture from fertilized pre-implantation embryos and possess 
pluripotency, meaning they can differentiate into any cell type within the body. Unlike adult stem 
cells, embryonic stem cells divide symmetrically, meaning a single cell can give rise to two new 
pluripotent stem cells 36, 37. This pluripotency and their indefinite renewal capacity are the main 
features that distinguish them from adult stem cells. Under defined conditions, embryonic stem cells 
are capable of replicating indefinitely and have thus been equally employed as a research tool as they 
have been explored for therapeutic potential 38. Studying the ways embryonic stem cells develop into 
mature cells have aided researchers in better understanding how those cells function as well as what 
goes wrong when they are diseased. As previously discussed, the tissue regenerative capacity of foetal 
cells vastly outpaces that of mature cells, and insight into cell and tissue healing during development 
may potentially be linked to the therapeutic possibilities of embryonic stem cells 38. Previous 
regenerative medicine approaches employing embryonic stem cells aimed to develop strategies that 
were capable of extending this enhanced embryonic regenerative capacity into the later stages of life. 
However, the requirements of fertilized human embryos to extract and culture embryonic stem cells 
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clouded their clinical use in ethical debate 38. As a result, the studies investigating the extensive 
regenerative potential of embryonic stem cells became secondary to finding less controversial sources 
possessing the same pluripotency and self-renewal features.  
 
Figure 3 – Current Stem Cell Sources 
The three main sources of stem cells are grouped into adult stem cells, embryonic stem cells, and 
induced pluripotent stem cells. Each stem cell source involves separate methods of derivation and 
give rise to stem cells with varying levels of potency which define their capacity to differentiate into 
various cell types within the body. 
 
1.1.2.1.2. Induced pluripotent stem cells 
In this manner, induced pluripotent stem cells (iPSCs) have revolutionised modern day stem cell 
research. Originating from any adult cell, iPSCs are generated by being reprogrammed to embryonic 
stem cell-like states using four transcription factors known as the Yamanaka factors (Oct4, Sox2, 
Klf4, and c-Myc) 39. Because the ethical issues surrounding embryonic stem cells do not apply to 
iPSCs, the idea that a patient’s own tissues could potentially provide them pluripotent stem cells for 
self-regeneration has become an increasingly possible reality. The ability to induce abundant, readily 
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accessible cells to pluripotency eliminates the search for rare tissue-resident stem cells while also 
providing the scalability of culturing clinically relevant quantities of stem cells. Additionally, while 
embryonic stem cells can only be derived from embryos, iPSCs offer patient-matched stem cells, 
overcoming the translational challenges of immune-rejection. The numerous benefits of iPSC 
technology have made it currently the most widely used approach for studying disease modelling 40 
and gene therapy 41. Although these studies are ongoing, the current literature surrounding iPSCs 
focuses mainly on characterising their pluripotency in comparison to embryonic stem cells and most 
importantly, defining the conditions necessary to generate all the individual cell types within the 
human body as conceptually theorized. Still in its infancy, a yet to be explored area of iPSC research 
is their potential to facilitate tissue regeneration through endogenous stem cell repair mechanisms. 
1.1.2.2. Stem cell mechanisms of regeneration: transdifferentiation vs paracrine 
Since the discovery of stem cell pluripotency, it is generally accepted that the therapeutic potential of 
stem cells resides in their ability to replace damaged cells within injured tissue on a cell by cell basis 
42, 43. This method of stem-cell mediated regeneration, known as transdifferentiation assumes that cell 
transplantation can overcome the inherent limitations of human regeneration by enhancing the overall 
numbers of stem cells or their lineages within injured tissue in attempts to overwhelm and speed up 
the repair process in order to ultimately curb fibrosis. For example, new cardiomyocytes identified 
following heart injury have been shown to express markers of transplanted cardiac stem cells 44. 
Additionally, mesenchymal stem cells transplanted into wounds have differentiated into fibroblasts 
45. However, while some beneficial effects in research models have been reported, no solid clinical 
evidence in humans has shown that these approaches are capable of regenerating damaged solid 
organs or giving rise to significant organ-specific cell populations, such as functional cardiomyocytes 
in the heart or beta cells in the pancreas 46. As a result, this concept of stem cell transdifferentiation 
has been routinely challenged and positive effects following transplantation therapies have been 
explained by alternative mechanisms (Figure 4).  
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There is mounting evidence that stem cells secrete a variety of growth factors 47, 
chemokines/cytokines 48, and bioactive lipids 49. In particular, it has been shown these factors are 
secreted from activated stem cells removed from their physiological niches. It is logical that these 
factors participate in alternative mechanisms of stem-cell guided regeneration based on paracrine 
effects. Distinct sets of paracrine factors specific to individual stem cell types have been shown to 
play a crucial role in regeneration of a variety damaged tissues 50. Recent data shows that harvested 
conditioned media containing these factors from stem cell populations such as haematopoietic (HSCs) 
or adult stem cells can even replace intact cells in cellular therapies 51. Conditioned media of 
mesenchymal stem cells (MSCs) derived in culture express pro-angiogenic growth factors such as 
VEGF and FGF-2, inflammatory chemokines such as macrophage inflammatory protein-1α (MIP-
1α) and monocyte chemotactic protein-1 (MCP-1), as well as inflammatory cytokines including TGF-
β and IL-10 52. The vast array of soluble factors released by stem cells are well known to the 
mechanisms of innate tissue regeneration and it is widely demonstrated that stem cells and their 
conditioned media can influence all stages of healing 51.   
In addition to soluble factors, activated stem cells also secrete spherical microvesicles from their 
membranes that significantly inhibit apoptosis of cells residing in damaged tissues, stimulate their 
proliferation and facilitate vascularisation 53. In addition to containing small packages of soluble 
factors, these microvesicles transfer mRNA or regulatory microRNA (miRNA) essential to their pro-
regenerative properties. Bone marrow derived-HSCs are capable of changing cell phenotypes to lung 
cells through delivery of lung-tissue derived microvesicles 54. Similar transfer mechanisms of organ-
specific mRNA into bone marrow cells have been demonstrated from microvesicles derived from 
brain, heart, and liver, suggesting that microvesicle-mediated changes in phenotype can occur 
universally throughout the body 54. These findings report an additional mechanism by which stem 
cell microvesicle release can drastically affect the phenotype and biology of neighbouring target cells 
following transplantation.  
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As the growing evidence suggests, stem cells have the potential to regulate the entirety of the body’s 
natural healing response. While it was originally believed that their role in tissue regenerative 
therapies would be to serve as the building blocks in the reconstruction of damaged tissue, it has 
become more apparent that their functions of coordinating regeneration may play a more dominant 
role. Further understanding of these mechanisms will lead to the development of improved stem cell 
therapies currently being used in regenerative medicine. Today, the mechanisms of stem-cell guided 
tissue regeneration are applied in numerous research and clinical studies. However, the transfer of 
many of these methods to the clinic is still met with a range of translational uncertainties which have 
largely hindered their widespread use to date.  
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Figure 4 – Mechanisms of Stem Cell Repair 
The two generally accepted mechanisms of stem cell tissue repair are through paracrine effects which 
rely on secreted regenerative factors that drive innate tissue healing and/or transdifferentiation 
which describes the direct differentiation of stem cells into the dysfunctional or loss cell type of the 
injured tissue/organ. 
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1.1.2.3. Current applications and clinical shortcomings 
In the past decade, there has been a rapid surge in clinical trials involving stem cell therapies 55. 
Currently, one of the most well-established and widely used stem cell populations are those found 
within the bone marrow. Transplantation of bone marrow HSCs is a common treatment for blood and 
immune system disorders as well as the current standard for restoring the blood system following 
cancer treatments 56. MSCs harvested from the bone marrow are currently being tested in over five 
hundred clinical trials for a very wide range of repair applications including cartilage, liver, kidney, 
lung, cardiovascular, bone, brain/nerves, as well as graft-versus-host and autoimmune diseases which 
exploit MSC’s immunosuppressive properties 57. The majority of these trials are in Phase I (safety 
studies), Phase II (proof of concept for efficacy in human patients), or a mixture of Phase I/II. 
Recently discovered in the bone marrow, endothelial progenitor cells (EPCs) are highly effective at 
stimulating angiogenesis and are a top focus of cardiovascular diseases. While efficacy in preclinical 
and Phase I trials have been demonstrated, patient benefit over placebo-controlled trials has yet to be 
obtained in Phase II 58. Overall, clinical trials on the use of stem cells are well underway for a wide 
variety of conditions with a particular emphasis on the use of bone marrow stem cell populations. 
While safety has been consistently demonstrated, sustained functional benefits have yet to be 
consistently obtained. Nevertheless, progress towards using stem cells for therapeutic benefit is 
increasing. A strong indication of the confidence in stem cell therapy is the growing participation of 
large pharmaceutical companies in stem cell research and funding of clinical trials 59.  With increased 
financial backing, the optimization of future stem cell based regenerative medicine approaches will 
be more readily achieved. 
However, despite the growing enthusiasm for therapeutic application, stem cells are burdened by 
several challenges observed in the clinic. Their intrinsic features of pluripotency and self-renewal are 
properties also inherent to cancer cells, and growing concerns about regulating stem cell behaviour 
in vivo to prevent tumour formation are continually discussed. In particular, iPSCs have shown 
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sizeable genetic and epigenetic abnormalities and there is a clear need to determine their biological 
significance before they are taken to clinical trial 59. Additionally, while the technology to induce 
pluripotency is now available, the logistical yields are still quite inefficient as will be discussed later. 
In cases where enough stem cells of a particular lineage can be generated, transplantation is still 
burdened by poor survival and subsequent transient benefits.  
Injured tissue is a difficult milieu for cell engraftment and survival due to lack of oxygen and 
nutrients, a dysfunctional extracellular matrix, and altered biochemical environments. As observed 
within the stem cell niche, certain signalling factors can have an impact on stem cell engraftment.  
For example, MSC engraftment is hindered by signals found within the hostile microenvironment of 
injured tissue that are derived from the highly inflammatory and cytotoxic processes occurring during 
the stages of healing 60. Another common lesson from engraftment studies is that transplantation of 
stem cells requires intact structural networks for survival. Interactions between the extracellular 
matrix and MSCs have shown that inadequate binding induces an apoptotic process known as anoikis 
61. Preventing anoikis involves activation of integrin receptors through matrix binding which then 
signal cell survival pathways. One of the established methods to address this issue is the use of 
artificial three-dimensional matrices to provide temporary structural support and biochemical cues, 
including integrin activation, to enhance cell survival.  
From extensive research and clinical findings, it appears that more needs to be understood about what 
regulates stem cell engraftment in vivo in hopes of translating their regenerative potential. This need 
has spurred the development of strategies which aim to augment stem cell engraftment to extend their 
functional benefits by providing adequate structural support following transplantation and/or ensuring 
that the necessary biomolecules are present to favourably enhance their survival. Today, an entire 
field within regenerate medicine exists to investigate engraftment solutions to appropriately fulfil this 
need. 
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1.2. Tissue Engineering 
Developing efficacious solutions to address the complexity of stem cell behaviour requires an 
interdisciplinary field combining the principles of engineering and life sciences towards achieving 
the goals of regenerative medicine. Representing that field today is Tissue Engineering, a set of 
research approaches that employ scaffold matrices to deliver growth factors and/or cells that have the 
ability to form tissues within the body upon transplantation. Interaction and integration with native 
tissues and cells are an underlying principle of tissue engineering which is why functionalisation of 
scaffolds with modifying factors such as biologically active proteins or DNA are critical to their 
success. Additionally, the target tissues involved usually require certain structural and mechanical 
properties essential to their function. Thus, the challenges in designing scaffolds with the appropriate 
biological and mechanical properties become increasingly overwhelming as the scale of the target 
tissue becomes more complex. Currently tissue engineering plays a relatively small role in patient 
treatment. The more successful procedures involve small scale repairs such as injection of cartilage 
forming chondrocytes for damaged cartilage 62 or grafting of skin cell sheets for damaged skin 63. 
Strategies to engineer supplemental bladders, arteries, kidneys, and lungs for example are still 
perceived as a long way from being fully reproducible and ready to implant into patients. However, 
despite the trials that lay ahead, the development of future successful strategies will rely on the same 
basic elements of current and past tissue engineering approaches.    
1.2.1. Tissue Engineering Paradigm 
Tissue engineering methods broadly utilise components of three essential pillars of what has become 
a common paradigm of the tissue engineering field (Figure 5). Tissue engineering strategies exploit 
numerous cell sources including autologous, allogenic, and stem cells. These cells are often utilized 
in combination with exogenous biochemical or biomechanical stimulation to regulate and/or augment 
their function in vivo. Meanwhile, scaffold matrices are used as growth and/or delivery platforms 
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containing both elements. Tissue engineering strategies typically exist and are categorized as various 
permutations of these pillars. Common examples are cell-seeded scaffolds, acellular scaffolds 
functionalised with biomolecules, biochemically enhanced cell populations, or functionalised 
scaffolds containing cell populations 64. While the use of various cell types and the biomolecule 
factors that dictate their function are also largely studied in regenerative medicine, tissue engineering 
seeks to develop approaches capable of translating their regenerative benefits to the patient’s bedside, 
primarily through the integration of biomaterial scaffolds. 
 
Figure 5 – The Tissue Engineering Paradigm 
The three major facets of tissue engineering; cells, scaffolds, and signals, that work in various 
combinations with one another to form the basis of the tissue engineering paradigm that underlies 
the development of all tissue engineering solutions. 
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1.2.2. Scaffolds 
Tissue engineering relies extensively on the use of 3D matrices known as scaffolds to provide the 
appropriate environment for tissue and organ regeneration. Acting primarily as a template for tissue 
formation, scaffolds are typically seeded with cells and/or growth factors. In some applications, these 
scaffolds are then subjected to biophysical stimuli within a form of ‘bioreactor’, a device or system 
which applies various mechanical and/or chemical stimuli to cells. Scaffolds are either cultured in 
vitro to synthesize tissues (often called a ‘tissue engineered construct’) which can then be implanted 
to an injury site, or are implanted directly into the injury site, using the body as a natural bioreactor 
to induce tissue and organ regeneration in vivo. Currently, scaffolds are manufactured from a wide 
range of biomaterials using a plethora of fabrication techniques, dictated largely by its application 
and target tissue 65. However, regardless of these variations in scaffold design, a few key 
considerations are essential to determining the scaffold’s suitability for use in tissue engineering  
(Figure 6). 
1.2.2.1. Essential scaffold features 
1.2.2.1.1. Tissue Compatability 
One of the first criteria for a tissue engineering scaffold is that it must demonstrate a positive 
interaction with cells. This property, known as tissue compatibility, determines the extent to which 
the body tolerates the scaffold. Cells must be able to adhere, maintain function, and proliferate on and 
throughout the scaffold before laying down new extracellular matrix. Following implantation, the 
scaffold or tissue engineered construct must also elicit a minimal immune reaction to prevent severe 
inflammatory responses which may impair healing and/or cause rejection by the body. Over time, the 
biocompatibility of an implant will help to determine the degree to which it seamlessly integrates 
with the target tissue. 
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1.2.2.1.2. Biodegradability 
The rate of scaffold integration is also closely linked to the scaffold’s replacement with the body’s 
own cells over time. Typically, scaffolds and constructs are not intended to function as permanent 
implants and must therefore exhibit properties of degradability. While the timing is difficult to 
accurately match, ideally, the scaffold would degrade at an equal rate to which cells are producing 
new extracellular matrix. The features of ‘bio’degrability would also require that the by-products of 
this degradation would be non-toxic and able to leave the body without negatively affecting other 
organs. As scaffolds and constructs have begun to be considered for use in clinical practice, it is 
becoming increasingly observed that allowing degradation to occur in tandem with tissue formation 
relies on the controlled infiltration of immune cells such as macrophages capable of facilitating 
degradation and tissue synthesis 66. 
1.2.2.1.3. Mechanical 
Another clinical perspective on scaffold requirements focuses on its mechanical properties. The 
scaffold must be strong enough to withstand surgical handling during implantation, while ideally, 
also possessing mechanical properties consistent with the anatomical site into which it is being 
implanted. Combined with degradability requirements, this is especially challenging for load bearing 
environments such as in cardiovascular and orthopaedic applications 67. The implanted scaffold must 
maintain sufficient mechanical integrity to function from the time of implantation to the completion 
of the regeneration process. As healing rates vary with age and medical condition, this becomes even 
more difficult to determine. Furthermore, while manufacturing current scaffolds with good 
mechanical properties is readily achievable, it is often at the expense of adequate scaffold porosity, a 
feature essential to the vascularisation and thus integration of the scaffold. It has become clear that 
although the architectural features of any scaffold are closely associated with its mechanical 
properties, they are equally important to its overall goals of successful tissue replacement.  
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1.2.2.1.4. Scaffold Architecture 
Scaffolds come in many shapes and sizes ranging from flat nanofibrous matrices to amorphous 
hydrogels. Typically, the intended application of a scaffold will dictate its required architecture. 
Scaffolds in sheet form may confront problems related to nutrient supply by limiting diffusional 
distances, while injectable matrices can tackle problems of surgical invasiveness. For example, a 
nanofibrous sheet would be more suitable for tissue layer regeneration applications such as skin, 
whereas a hydrogel would benefit injuries with more irregular architecture such as brain or heart 
injury. While the overall architecture of many scaffolds used in tissue engineering may vary, high 
porosity remains an architectural feature crucial to the success of any scaffold 68. An ideal scaffold 
would have an interconnected pore structure allowing cell penetration and subsequent exchange of 
nutrients and waste, achievable primarily through the stimulation of angiogenesis throughout the 
scaffold pores. Pore distribution and diameter are adjustable architectural parameters to help regulate 
new matrix deposition and scaffold degradation. Therefore, depending upon the cell type used and 
target tissue being engineered, a critical range of porosity properties must exist within the scaffold. 
These essential scaffold features are critical to success in tissue engineering applications and are 
closely associated with one another in determining their outcomes 69. However, one criteria upon 
which all the required properties listed above are dependent upon is the choice of biomaterial from 
which the scaffold is fabricated. 
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Figure 6 – Biomaterial Scaffold Properties 
The essential properties of biomaterial scaffolds taken into consideration when designing scaffolds 
for tissue engineering 
 
1.2.2.2. Biomaterials 
As the field of tissue engineering grows, scaffold materials continue to evolve from merely interacting 
with the body to influencing biological processes that facilitate tissue regeneration.  Scaffolds are 
typically manufactured from three groups of biomaterials: ceramics, synthetic polymers, and natural 
polymers (Figure 7). 
1.2.2.2.1. Ceramics 
Most commonly used for hard tissue bone applications are ceramic scaffolds 70. Ceramic scaffolds 
are typically known for high mechanical stiffness (Young’s modulus), very low elasticity, and hard 
brittle surfaces. For bone applications, ceramics intrinsically exhibit excellent biocompatibility with 
osteogenic cells, cells involved in bone formation. This is due to their closeness to the mineral phases 
of native bone in both chemical and structural similarity. Various ceramics are used directly in dental 
and orthopaedic surgery to fill bone defects as well as for coatings of metal implants to improve 
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implant integration with native bone. However, widespread use in tissue engineering applications 
have been limited due to their brittleness, difficulty in shaping, and challenges in controlling 
degradation rate in relation to new bone formation 71. As previously discussed, porosity greatly 
compromises the mechanical integrity of ceramics and often the mechanical loads in bone 
environments cause ceramic scaffolds to fracture. Improved control of mechanical properties is a 
heavily researched area of ceramic manufacturing. This has led to the popularity of alternative 
materials such as synthetic polymers which offer more tuneable mechanical features. 
1.2.2.2.2. Synthetic Polymers 
To date, a vast range of synthetic polymers have been researched for their potential use in both soft 
and hard tissue applications, including polypropylene (PP), polyethylene (PE), polystyrene (PS), 
nylon, and polyurethane (PU). The popularity of these synthetic polymers for tissue engineering 
scaffolds stem from their ease of fabrication with tailored and reproducible architecture, mechanical 
properties, and degradation by simply varying the polymer itself or composition of the individual 
polymer 72. However, concerns exist about the biodegradation of some synthetic polymers which 
produce acidic by-products and carbon dioxide which can lower local tissue pH leading to cell and 
tissue necrosis. For example, Poly(lactic-co-glycolic acid) (PLGA) is a commonly used synthetic 
polymer for a range of tissue engineering applications from stem cell-loaded contructs to bone 
applications.  However, their use has been associated with an increase in localised acidic pH at the 
site of implantation that instigates inflammation and subsequent fibrosis 73. While these features are 
readily tuneable, mechanical properties are often compromised early during degradation, thus 
polymer selection is limited to distinct applications. At the foremost, these materials are also known 
to exhibit poor biocompatibility and have an increased risk of rejection by the body. For instance, 
expanded polytetrafluoroethylene (ePTFE), currently the most widely used polymer for synthetic 
vascular graft shows poor endothelial cell attachment both in vitro and in vivo due to their high 
hydrophobicity 74. The exchange of biocompatibility for increased control over scaffold mechanical 
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properties requires additional methods to functionalise scaffold surfaces with cell compatible binding 
domains like the Asp-Gly-Asp (RGD) motif found in native matrix proteins 75. To avoid these 
additional fabrication processes, alternative approaches utilize native biological materials. 
1.2.2.2.3. Natural Polymers 
Biological polymers found in nature and have been extracted from a range of biological species 
including rodents, crustaceans, insects, plants, and bacteria 76, 77. Natural polymers typically consist 
of components found in the native extracellular matrix, which unlike synthetic polymers, make them 
inherently biological active, capable of promoting excellent cell adhesion and proliferation. For 
example, collagen is one of the most widely used and researched natural polymers for biomedical 
applications and has been extracted from numerous sources including bovine skin and tendons, 
porcine skin, intestine, and bladder mucosa, and rat tail. As a native component of the extracellular 
matrix (ECM), collagen electrospun grafts supports the infiltration of fibroblasts for appropriate heart 
tissue remodelling following myocardial infarction 78. Additionally, natural polymers are 
biodegradable with non-toxic by-products, allowing host cells to produce their own extracellular 
matrix and replace the scaffold over time as it degrades. For instance, one commonly investigated 
polymer for wound dressings is alginate, a polysaccharide derived from brown seaweed. Alginate 
polymers biodegrade naturally into non-toxic byproducts and thus have shown minimal inflammatory 
and foreign body reactions in wound healing studies 79. However, fabrication of natural polymer-
based scaffolds with homogenous and reproducible architectures remains challenging 77. This is 
mainly due to variability of processing of the raw material which often results in changes to polymer 
structure. For example, chitosan, a heavily researched polymer for cartilage, nerve, and tissue 
engineering, exhibits poor mechanical weakness due to the disruption of its native molecular weight 
distribution and/or degree of acetylation during its extraction from the exoskeleton of shellfish 80. The 
inefficient processability of natural polymers also contributes to their generally poor mechanical 
properties which often limits their use in load-bearing applications, which has spurred the 
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investigation of another class of materials incorporating blends of both synthetic and natural 
polymers.   
1.2.2.2.4. Composite scaffolds 
The increasing trend of tissue engineering applications is the use of composite scaffolds which rely 
on the combination of biomaterials to appropriately balance their individual advantages and 
disadvantages. Typical composite scaffolds are those comprised of blends of synthetic and natural 
polymers, to provide appropriate mechanical properties while improving biocompatibility, 
respectively 81. For example, blends of PCL with collagen (PCL/Collagen) for use in vascular tissue 
engineering have been demonstrated to enhance smooth muscle cell proliferation and growth while 
also increasing overall scaffold tensile strength 82.  Designing composite scaffolds of two or more 
materials often presents itself with increased complexity when attempting to regulate scaffold 
properties such as biocompatibility and/or biodegradation. Determining the appropriate amount of 
each composite constituent remains an ongoing challenge of scaffold design and involves mostly 
trial-and-error methodology. For example, recent work developing an ideal composite 
alginate/hydroxyapatite scaffold for bone ingrowth required an array of manufacturing parameters, 
most notably the investigation of a wide range of hydroxyapatite concentrations 83. This process 
painstakingly investigated individual hydroxyapatite concentrations from 5-20% (w/v), in order to 
fabricate a suitable scaffold to study osteoblast compatibility 83.Further accentuating this challenge 
of scaffold design is the need for biomolecules to be incorporated into the scaffold architecture. 
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Common Scaffold Biomaterials 
Ceramics Synthetic Polymers Natural Polymers Composites 
Alumina 
 
Zirconia 
 
Hydroxyapatite 
 
Calcium Phosphate 
 
Polycaprolactone (PCL) 
 
Polytetrafluoroethylene 
(PTFE) 
 
Poly(lactic-coglycolic 
acid) 
(PLGA) 
 
Collagen 
 
Alginate 
 
Chitosan 
 
Hyaluronan 
PCL/Collagen 
 
PCL/Chitosan 
 
Hydroxyapatite/ 
Alginate 
Figure 7 – Common Scaffold Biomaterials 
Table of common classes of materials used in biomaterial scaffold fabrication and examples of the 
most commonly researched materials 
1.2.3. Scaffold functionalisation 
A considerable research area within scaffold design has been the adaptation of modification 
techniques aimed at improving scaffold properties such as biocompatibility and/or regulating 
biological processes, such as stimulating vascularisation. Today, the most promising scaffolds are 
typically comprised of synthetic materials that lack cell recognition sites. Therefore, the introduction 
of functional groups onto the scaffold surface is crucial and can serve as cell recognition sites or focal 
points for additional modifications with bioactive molecules. Surface functionalisation can be 
beneficial in regulating cell behaviour in vitro and in vivo, as well as provide favourable control over 
biological responses to the scaffold or construct following implantation. The study of biomolecular 
functionalisation will lead to promising bioactive materials with the ability to dynamically adapt to 
native tissue microenvironments meanwhile directing cellular function towards tissue regenerative 
outcomes. 
1.2.3.1. Surface chemistry modification  
Scaffold surface chemistry properties including hydrophobicity, surface charge density, micro-
topography, and specific chemical groups can all impact a range of cellular behaviour including 
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adhesion, growth, migration, differentiation, matrix synthesis, and tissue morphogenesis 84. 
Functional modifications of surface chemistry are thus crucial to inhibiting unfavourable cell effects 
while enhancing beneficial cell behaviour. Various modification methods are currently exploited to 
alter surface chemistry, impacting cell behaviour directly, or indirectly by providing functional 
groups to be used for the conjugation of bioactive molecules.  
1.2.3.1.1. Wet chemistry approaches 
A commonly practiced method of surface chemistry modification is by incubating scaffolds in 
aqueous chemical solutions for extended periods of time. Alkaline solutions have been shown to 
impart rough hydrophilic surfaces to biodegradable polymers which associates to improved cell 
morphology and viability. These wet approaches catalyse the cleavage of polymer backbones through 
accelerated hydrolysis, exposing organic chemical groups, such as carboxylic acid and hydroxyl 
groups, more readily recognizable to cells. Hydrolysis a simple and frequently used method of 
chemical functionalisation, however it is lengthy, highly pH dependent and leads to some degree of 
unwanted degradation of the polymer surface, negatively impacting bulk scaffold properties such as 
mechanical integrity.  
Additionally, carboxylic acid groups require further ‘activation’ by turning the acid into a more active 
derivative or through chemical linkers for biomolecule conjugation. This is most commonly achieved 
through incubation in 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) and N-
hydroxysuccinimide (NHS) buffered aqueous solutions that react with primary amines on proteins 
side chains and increase their coupling efficiency to the exposed carboxyl groups 85. However, 
concerns about facilitating the same reactions between carboxyls and amine groups on proteins may 
result in unwanted crosslinking, folding, and/or aggregation of the molecules. Covalent linkages 
using chemical linkers have thus been developed to form more specific bridges within molecules 
through chemical groups such as thiols or amino acids such as cysteines 86. However, the use of 
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linker-chemistry approaches is also limited because they are effective only on surfaces pre-treated 
with distinct functional groups, as well as rely heavily on wet chemistry reactions that are often 
complex, possess unwanted side-reactions, yield high variability, and often involve toxic solvents.  
These challenges highlight the need of alternative functionalisation methods.  
1.2.3.1.2. Plasma immersion ion implantation 
Functionalisation of scaffold surfaces through plasma treatment is becoming increasingly popular due 
to its simplicity and efficiency. Plasmas are generated by ionising a neutral gas, such as nitrogen, to 
a strong electromagnetic field. Incubation of biomaterial surfaces in plasma leads to chemical and 
physical modifications through electrons, ions, and radicals. Studies into plasma functionalisation 
have revealed that the energetic ion bombardment of the scaffold surface can yield radicals embedded 
in carbon rich surface layers. This functionalisation method, known as plasma immersion ion 
implantation (PIII), has been demonstrated to facilitate the covalent immobilisation of numerous 
biomolecules to a range of polymeric surfaces, all while retaining their biological function 87(Figure 
8). Biomolecule immobilisation occurs in a single step directly from solution in native 3D 
conformations retaining their bioactivity. In these studies, covalent immobilisation was demonstrated 
by showing that immobilisation biomolecule surface layers were resistant to aggressive detergent 
washing protocols. Additionally, PIII treatment can be applied to any underlying material without 
affecting bulk scaffold properties 87. This alternative approach simplifies the process of decorating 
scaffold surfaces with favourable biomolecules by delivering the strength and stability of covalent 
attachment, while eliminating the requirements and drawbacks of multi-step wet chemistry.  
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Figure 8 – Plasma immersion ion implantation (PIII) 
PIII surface functionalisation involves the ionizing of a nitrogen gas to impart mobile radicals into 
the surface of an underlying polymer. Polymer substrates are placed into a plasma chamber and 
following PIII treatment, are capable of single-step surface immobilisation of biomolecules directly 
from solution. 
1.2.3.2. Bioactive molecule incorporation 
Unlocking the full potential of regenerative medicine and tissue engineering relies on controlling the 
delivery of biomolecules into the cellular microenvironment. Typically, this has been investigated 
through bioengineered materials and/or cells capable of spatiotemporal modulation of biomolecules 
release and presentation. The types of biomolecules incorporated into scaffolds can function either 
from the outside-in through the delivery of soluble and insoluble factors, such as proteins and 
cytokines, which signal by binding receptors on the outside of cells, or from the inside-out through 
the transfer of reprogramming genes. Although the biomolecules chosen are well-known to the target 
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tissue application and desired biological responses, it often the delivery and presentation methods 
which are crucial to their effectiveness in tissue engineering. 
1.2.3.2.1. Release strategies 
The simplest method of generating scaffolds containing functional biomolecules is by allowing the 
biomolecules to diffuse into and/or absorb into the scaffold. For example, porous scaffolds seeded 
with cells ex vivo are incubated in bioreactors with growth factor-rich media which infiltrate the 
scaffold through convection and diffusion 88. In an effort to better mimic native physiologically 
environments, growth factors have been incorporated into matrices such as hydrogels, which release 
their loaded cargo during degradation 89. In these cases, wet chemistry conjugations are often used to 
bind growth factors to polymer backbones. An alternative method is to utilize particulate delivery 
systems for controlled release. Micro- and nanoparticles fabricated from polymers incorporate 
therapeutic agents through the particle on loaded in their cores 90. This prevents the cargo from 
biological degradation and clearance from the body, extending their functional bioactivity. Another 
advantage is the controlled release of the encapsulated cargo over time. 
While numerous biomolecule release strategies exist, regenerative medicine applications typically 
require the synergistic functions of numerous factors and thus the temporally controlled sequential 
delivery of multiple biomolecules can often be challenging. Furthermore, although the rate of factor 
delivery may be regulated, the spatial localisation of the cargo is subjected to passive diffusion away 
from the implant site. This is more evident in dynamic flow environments such as in the 
cardiovasculature. Limited control over where soluble factors localise following delivery can often 
hinder the targeting of desired biological responses. 
1.2.3.2.2. Covalent immobilisation 
In covalent surface immobilisation, biomolecules are chemically bonded to the scaffold surface, 
resulting in a more efficient coating with longer retention compared to adsorption/release strategies. 
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As previously discussed, this can be achieved through linker or linker-free functionalisation 
treatments. Immobilisation results in a layer coating of biomolecules providing cues to facilitate target 
biological responses originating at the scaffold surface.  For example, metallic stents have been 
immobilised with the antibodies specific for endothelial cells to facilitate increased endothelial cell 
covered on the stent surface 91. As demonstrated in these studies, immobilisation can retain biological 
activity in high flow/dynamic environments. 
While immobilisation strategies offer more control over the localisation of biomolecule delivery, 
these approaches possess their own set of drawbacks. Achieving the temporal presentation of multiple 
factors is not possible as they will exist as a cohesive layer on the exposed surfaces of the scaffold. 
Furthermore, the dosages of immobilised factors are limited by the surface area of the scaffold and 
can be significantly less in magnitude to the amount capable of being loaded in release delivery 
systems. Therefore, biomolecules for covalent immobilisation should be chosen as potent signalling 
factors capable of acting on multiple cell types and/or stimulating self-sustaining biological 
responses. Because the available surface area of the scaffold dictates the amount of biomolecule that 
can be presented through immobilisation, utilisation of this functionalisation method is often 
associated with the process of scaffold fabrication and the resulting scaffold architecture. 
1.2.4. Electrospinning 
Over the past decade, one of the fastest growing scaffold fabrication methods in research and 
commercial attention has been electrospinning 92. Electrospinning is an electrostatic fabrication 
technique which produces polymer fibers ranging from nanometres to micrometres. Due to the 
common research goals of tissue engineering, the popularity of electrospun scaffolds has increased 
as their intrinsic nanofibrous topography is seen as a close working template to mimicking the native 
extracellular matrix. The general acceptance of electrospinning in the field of tissue engineering is 
evident by the fact that hundreds of universities and research institutes worldwide are investigating 
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the various aspects of the electrospinning method, and this is matched closely to the number of patents 
for electrospinning-based applications.  
 
Figure 9 – Electrospinning Apparatus 
Electrospinning is a fiber production method that uses electric force to draw charged threads of 
polymer solution into fiber diameters in the order of hundreds of nanometres. Adapted from 92 
 
1.2.4.1. Basic principles 
Using electrostatic forces, electrospinning produces fine fibers from polymer solutions, both natural 
and synthetic 92. The typical electrospinning apparatus utilizes three main components: a high voltage 
power supply, a spinneret, and a grounded metal collecting target (usually a screen, plate, or rotating 
mandrel) (Figure 9). Before the electrospinning process, polymers are dissolved in solvents to form 
polymer solutions. Because some polymer may emit unpleasant or harmful odours, electrospinning 
is often conducted within ventilated chambers. Direct current (DC) voltages in the range of tens of 
kilovolts (kVs) are required to generate electrostatic forces which charge the polymer solutions to a 
critical value where the electrical forces on the liquid overcomes the surface tension in the polymer. 
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This extrudes the polymer to form a Taylor cone, after which an unstable and rapid whipping of the 
solution jet occurs. During this process the diameter of the polymer solution decreases due to solvent 
evaporation. Once reaching the collection target, the polymer solution will have transitioned into a 
solid phase forming an individual fiber. Continual collection of these fibers form multilayered fibrous 
structures.  
1.2.4.2. Fabrication parameters 
The electrospinning process and the architecture of the resulting fibrous scaffolds are governed by 
numerous process parameters, including applied electric field, distance from tip to collecting target, 
and solution flow rate. Appropriate manipulation of these parameters produces nanofibers of desired 
diameter and morphology which then relay bulk scaffold properties such as porosity. One of the most 
systemically studied processing parameter on scaffold architecture is flow rate 93. 
Flow rate influences the solution velocity from the syringe. A lower feed rate is more desirable for 
allowing solvent evaporation to occur before reaching the collection target. Numerous studies have 
confirmed that fiber and pore diameter of electrospun scaffolds increase with polymer flow rate 93. 
Larger fibers typically yield increased surface area, scaffold features that become important for cell-
scaffold contact as well as biomolecule immobilisation. However, at significantly high flow rates, 
even fiber morphology is lost as beaded fibers are observed because polymer solutions are not allowed 
to evaporate properly being reaching the collection target 94. 
The expanding use of electrospun scaffolds in tissue engineering applications stems from easily 
tuneable scaffold parameters. Some of these advantages include high surface-to-volume ratio, 
porosity, wide range of three dimensional conformations, and limitless combinations of nanofiber 
composition. Scaffold characteristics can be tailored by simply changing single processing 
parameters such as flow rate. The conformations of electrospun scaffolds are determined by the type 
of collection target and have previously been spun into sheets, tubes, blocks and even biologically 
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inspired tissues such as heart valves. Furthermore, scaffold composition is determined simply by the 
polymer or polymer blends that are loaded into the syringe. In addition to fiber morphology, fiber 
composition also plays a role in determining essential scaffold features such as mechanical properties 
and degradation.  
1.2.4.3. Application in tissue engineering 
The intrinsic fibrous topography of electrospun scaffolds is viewed as essential for cell seeding, 
invasion, proliferation, and differentiation prior to the regeneration of biologically functional tissue 
or extracellular matrix. Numerous studies investigating a wide variety of cell types have reported that 
these scaffolds positively promote cell-matrix and cell-cell interactions, with cells maintaining 
normal phenotypes, morphologies, and gene expression 95-97. The diameter of electrospun fibers can 
be fabricated in similar size to that fibrils of the extracellular matrix, and with the versatility of 
spinning natural polymers such as collagen, mimicking the native tissue environment becomes more 
attainable and increases the likelihood of improving cellular behaviour such as engraftment. 
Additionally, functionalisation treatments with biomolecules can improve these features even further. 
Electrospun scaffolds have been utilized in numerous tissue engineering applications include, 
cartilage 98, dermal tissue 99, arterial blood vessels 100, heart 101, and nerves 102.  
1.2.4.4. PCL electrospun scaffolds 
Of the many polymers currently used for electrospinning, poly(ε-caprolactone) (PCL) is the most 
widely researched polymer in tissue engineering 103. PCL has good biocompatibility, excellent 
biodegradability, exhibits slow degradation rates (2-4 years depending upon the starting molecular 
weight) and has suitable mechanical properties for a variety of tissue engineering applications. 
Supporting its popularity is a history of use dating back to 1980 and FDA approval as a medical 
material for slow release drug delivery devices and sutures. However, one of the main disadvantages 
of PCL is its hydrophobicity, resulting in poor wettability, lack of cell attachment and uncontrolled 
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biological interactions. Surfaces with increase hydrophobicity generally lead to the poor absorption 
of proteins and subsequent unfolding and therefore poor cell attachment. This issue is largely 
addressed through the incorporation of biologically active components using two previously 
discussed methods. The first is by blending PCL with appropriate amounts of natural polymers like 
collagen. The second is through surface functionalisation of bioactive molecules.  
However, while PCL serves as an excellent starting template for the development of many tissue 
engineering scaffolds, there remains an ongoing challenge in tailoring them for specific tissue 
engineering applications. The design parameters to choose from include limitless copolymer blends 
and ratios, functionalised biomolecules, and mechanical dimensions. These are also separate to the in 
vivo challenges of inflammatory foreign body responses which can impair scaffold function following 
implantation. Raising these concerns highlights some of the translational challenges which must be 
overcome before these scaffolds can be considered for clinical use.  
1.3. Translational Scaffold Design Challenges 
Tissue engineering scaffolds are subject to numerous design constraints which demand specific 
features previously discussed, including vascularisation, degradation, mechanical properties, and 
biocompatibility. While these properties are often exemplified in research studies, the manufacturing 
of these scaffolds must also occur within clinically relevant timelines with appropriate assurances of 
safety, sterility, stability, and cost-efficiency. Developing tissue engineering scaffolds for clinically 
relevant application requires a delicate balance between efficacious scaffolds and robust, scalable, 
and affordable production methods. The commercialisation of tissue engineering solutions also 
requires off-the-shelf properties which determine the levels of practicality for therapeutic 
intervention. It is often the case that promising findings in research studies are either too complicated 
to produce and/or do not consider the range of clinical challenges arising along the path of scaffold 
development, implementation, and integration. In this regard, while many of the beneficial effects of 
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current scaffolds and constructs are often reported, the need for tissue engineered solutions that can 
wholly integrate with the human body still exists. As previously discussed, tissue engineering 
solutions for creating complete and functioning full organs are still not achievable. Even for smaller 
applications, implants that last the lifetime of the patient are rare. The ability to integrate with the 
human body over time is the first step towards efficacious design and translation of the beneficial 
properties of tissue engineering solutions.  
1.3.1. Host integration 
As tissue engineering and regenerative medicine are considered for use in the medical care setting, 
the integration of these solutions with the surrounding natural tissue environment of treated patients 
is of paramount importance. Although certain stem cell types have achieved short-term success as 
therapies for various diseases, it is still unclear whether they are capable of forming whole new tissues 
themselves or stimulate local cells to regenerate. In either case, the resulting outcome is typically 
poorly connected to the surrounding tissue environment and functionality of the tissue engineered 
scaffold/construct is drastically impaired after a few months. Genuine integration can be achieved by 
designing bioactive materials that not only act as scaffolds for cells to adhere to and form new tissue, 
but also provide cues and signals that regulate the innate biological responses that are crucial to and/or 
hinder integration.  
1.3.1.1. Mass transport through vascularisation 
Several techniques exist for the creation of cellularised scaffolds, but constructs that match the 
cellular density of native tissue and organs remains a challenge in tissue engineering. Increased cell 
density requires an increased demand for infrastructure capable of mass transport, such as oxygen 
and nutrients exchange with cell products and waste. As previously discussed in close association 
with scaffold porosity, mass transport is an important aspect of scaffold integration. Diffusion is an 
inadequate method of mass transport when it comes to the scale of full tissue and organ regeneration. 
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This is particularly the case in regards to scaffolds and constructs that seek to replace organs with 
endocrine functions 104. Cells must have close proximity to a functioning and stable blood supply in 
order to sense physiological indicators and respond appropriately, while also allowing access to 
nutrients necessary to their survival.  
Strategies to address mass transport include promoting pre-vascularisation of the scaffold or construct 
prior to implantation, or guide in situ vascularisation once the material has been implanted. Pre-
formation of vasculature has been explored through the seeding of endothelial cells as part of cell-
laden constructs 105.  In combination with porous structures, tubular structures can be formed in vitro 
which can then form functional vascular elements or fuse with native vessels once implanted 106. 
Guided vascularisation in vivo is primarily achieved through recruitment of host cells through the 
scaffold to participate in angiogenesis. Potential targets include leveraging the pro-angiogenic 
function of macrophages, along with the engineered delivery of pro-angiogenic factors such as VEGF 
and FGF-2 107. Such strategies rely on continual interactions with the surrounding biological 
environment, and thus ensuring these interactions are able to take place is a crucial factor to long-
term tissue integration and eventual regeneration.  
1.3.1.2. Foreign body response 
One of the first host reactions towards an implanted biomaterial is the activation of a foreign body 
response 108 (Figure 10). Foreign body responses are inflammatory driven processes conserved as 
protective mechanisms to defend the body from foreign pathogens. The outcomes of the foreign body 
response are isolation of the implant, preventing biological interaction with the surrounding 
microenvironment. Without intervention the foreign body response can severely impact the function 
of scaffolds serving as structural support, drug delivery vehicles, sensory devices, electrical devices 
or constructs containing proteins, cells, and other biological components 108. Consideration of the 
foreign body response when designing the scaffolds for tissue engineering is essential to improving 
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its long-term biocompatibility, safety, and function. Mitigating the foreign body response involves a 
deeper understanding of the biological process which regulate its activation in order to identify 
suitable target cells and/or signalling factors. 
1.3.1.2.1. Innate immune response 
The implantation of a biomaterial activates the same mechanisms of wound healing with one of the 
primary stages being the activation of the innate immune response. However, the extent and degree 
of inflammatory activation is determined by the extent of injury during the implantation procedure, 
the tissue or organ into which the biomaterial is being implanted, and the size of the 
implant/provisional matrix formation. As previously discussed, monocyte-derived macrophages 
facilitate numerous roles throughout the innate wound healing process. In response to biomaterial-
mediated immune responses, macrophages play an even larger role in facilitating inflammation 109. 
When macrophages arrive at the surface of an implant, they initiate phagocytotic functions in an 
attempt to engulf the implant. When the implant is too large, the formation of an adherent layer of 
inflammatory macrophages results on the implant surface. In normal wound healing mechanisms, 
acute inflammation is generally followed by immune resolution through the degranulation of 
leukocytes, signalling apoptosis and anti-inflammatory cytokine release from macrophages. 
However, in response to biomaterials, because macrophages are unable to phagocytose the implant, 
chronic inflammation occurs, involving the further recruitment of inflammatory cells, and 
macrophages fuse to form foreign body giant cells (FBGC). Through the release of inflammatory 
mediators, reactive oxygen species and enzyme production, macrophages and FBGC create a low-pH 
microenvironment at the implant surface that acts synergistically with its secreted factors to damage 
the material surface through degradation mechanisms such as oxidative chain cleavage, hydrolysis, 
or stress cracking. Degradation leads to compromises in structural integrity, function, and ultimately 
safety of the implant.  
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1.3.1.2.2. Fibrotic capsule formation 
Once chronic inflammatory responses have determined the material cannot be engulfed, it is 
effectively walled off from the local tissue environment by fibrous encapsulation. The thickness of 
the fibrous capsule around the material is often used as an assessment of a material’s biocompatibility. 
Collagen is the main constituent of fibrous capsules, synthesised by fibroblasts in concentric layers 
around the implant. The capsule creates a physical barrier between the material and the local 
biological environment. As a result, mass transport from the scaffold is significantly reduced. In 
biosensing devices, the fibrous capsule induces significant delays if not complete loss in 
measurements of desired analytes 110. In drug delivery systems and cell seeded constructs, it obstructs 
the therapeutic effects of the drug and biomolecule release, as diffusion through the capsule towards 
adjacent target tissue is limited or absent.  
1.3.1.2.3. Macrophage polarisation 
Macrophage activation is a central inflammatory theme of both innate healing mechanisms and 
foreign body responses. The phenotypes of macrophages exist along a spectrum of polarisation states 
related to their functional diversity. At one end of the spectrum are pro-inflammatory “M1”, and at 
the other end are anti-inflammatory “M2”. In the context of biomaterial implantation, M1 
macrophages express inflammatory antigens such as major histocompatibility complex class 2 (MHC 
Class II) and initiate immune response that leads to the recruitment of inflammatory cells through the 
production and release of inflammatory cytokines such as interleukin-1β (IL-1β) and tumour necrosis 
factor-α (TNF-α) 111. M2 anti-inflammatory macrophages consistently express mannose receptors 
(CD206) and release anti-inflammatory cytokines such as IL-10 and TGF-β 111. The presence of such 
anti-inflammatory cytokines within the tissue remodelling process has been reported to aid in the 
vascularisation of numerous biomaterials.  
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Unlike terminally differentiated cells, macrophages are capable of switching polarisation states in 
response to their microenvironment, and this transitory nature is often related to their paracrine 
signalling functions. For example, the induction of pro-inflammatory cytokine release following 
lipopolysaccharide (LPS) stimulation of macrophages can be significantly dampened in the presence 
of interleukin-4 (IL-4), a M2 polarising cytokine released by nearby M2 macrophages and other 
leukocytes 112. This suggests that the presence of macrophages in different polarisation states within 
the same microenvironment can potentially be harnessed. As a result, well-established M2 polarising 
cytokines such as IL-4 are highlighted as potential therapeutic biomolecules to minimize 
inflammatory responses and induce constructive modelling. 
 
Figure 10 – Foreign Body Response (FBR) 
The FBR is a biological response to any foreign material implanted into the tissue characterised 
mainly by the accumulation of inflammatory cells of the innate immune system on the surface of the 
implant which then leads to the encapsulation of the implant in a fibrotic capsule that serves to isolate 
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it from the surrounding biological tissue. The foreign body response hinders the efficacy and safety 
of any medical device implanted into the body. 
1.3.2. Time and cost constraints 
Besides demonstrating numerous biological benefits, the clinical and commercial success of tissue 
engineering products relies on its time and cost-effectiveness, highlighting an additional challenge in 
balancing sophistication and ease of production. The time required to produced full-sized tissue 
replacements depends on the manufacturing of the scaffold and/or generation of sufficient quantities 
of therapeutic cells. More specifically the required time to prepare tissue engineering solutions is a 
large determinant of their clinical translation as is often referred to as its “off-the-shelf” property. 
Characterisation as off-the-shelf requires that fabrication time frames match those of the clinical need 
of the patient. Additionally, more time and complexity associated with fabricating the scaffold or 
preparing it for implantation translates to higher costs. Several advancements have been made in areas 
of rapid or high-throughput manufacturing of biomaterial scaffolds, such as in-line production 
methods and automated printing 69. However, the pace of producing therapeutic cell types remains an 
ongoing challenge.  
1.3.2.1. Cellular vs acellular approaches 
Bioreactor systems have been developed to generate large quantities of stem cells, however the 
capability of reliably producing fully differentiated cells in clinically relevant timeframes remains an 
unmet need 113.  Once sufficient numbers of cells are generated, primary cells have limited time 
windows for use, as they become senescent in later passages 114. In applications where they may be 
required to repeatedly proliferate, this may present a problem. However, this does not really affect 
applications where their paracrine effects are needed for a relatively short amount of times, enough 
to stimulate biological processes such as angiogenesis. Additionally, the cell source of constructs 
presents an additional bottleneck in manufacturing. Because of possible immune rejection and the 
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requirement of life-long immunosuppressive treatment, the increasing trend of cell-based tissue 
engineering therapies is moving towards re-engineered allogenic or xenogeneic stem cell sources that 
can potentially evade host detection. However, these traits also lay the potential foundation for cancer 
cells and tumour formation. Alternatively, with constructs based on autologous cells, tissue samples 
must first be harvested from patients individually, followed then by isolation, expansion and seeding. 
This production chain represents batch processing methods rather than continuous processing 
extending both time and costs. Improving the scalability and efficiency of stem cell production relies 
on advances in stem cell biology. Concurrent to these research studies, tissue engineering approaches 
using acellular scaffolds are also be investigated and their translational challenges considered. 
Some of the obvious challenges to large-scale manufacturing of biomaterial scaffolds is the 
requirement to be specifically tailored to individual patients. A “one size fits all” mentality towards 
tissue engineering is unrealistic considering that the anatomy, physiology, and regenerative capacities 
differ within patients and amongst disease states. Relying on the endogenous healing potential of 
individuals, especially when comparing healthy to diseased patients, may require different doses of 
functionalised biomolecules, which are crucial to the biological function of acellular scaffolds. 
Additionally, as the behaviour of infiltrating cells are determined by the surface chemistry and 
composition of the scaffold, manufacturing considerations of scaffolds should also be considered.  
1.3.2.2. Scaffold manufacturing  
Scaffold composition determines the types of materials required and thus related time and costs of 
manufacturing. When blends of both synthetic and natural materials are balanced for purposes of 
achieving desired scaffold properties, such as biocompatibility or biodegradation, manufacturing 
considerations must also be taken to factor in costs and feasibility of preparation. Synthetic materials 
like PCL are typically cheap to produce and can be manufactured in large batches with high 
reproducibility. On the other hand, natural materials such as collagen are often expensive to derive, 
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and processing methods typically have small yields with high variability between batches. To 
overcome this, cheaper derivatives such as gelatin (a low-cost denaturation product of collagen) are 
typically employed, although higher percentages are often required within the composite to account 
for diminished biological properties 115. Adding considerations of time and cost-effectiveness of 
materials chosen for scaffold fabrication poses additional hurdles within the challenges of scaffold 
design.  
In addition to creating scaffolds with multiple materials, the need for controlled architectures and 
multiple deliverable biomolecules is almost impossible with a single-step fabrication process. The 
processes contributing major delays to fabrication are conventional functionalisation methods which 
typically involve multiple steps in the time scale of days 65. Pre-functionalisation of implants would 
also exhibit very poor off-the-shelf properties as the decorated biomolecules outside of reconstitution 
buffers would most likely possess minimal shelf-lives. Thus, biomolecule functionalisation would 
have to occur on-demand requiring increased preparation times prior to implantation. However, with 
the advent of plasma surface treatments such as PIII, some of the translational time constraints of 
conventional functionalisation methods would be drastically reduced to a single step process. 
Furthermore, the shelf-life of the functional groups imparted by PIII have been previously validated 
to last up to one year, meaning pre-functionalised implants could sit on the shelf and rapid 
functionalisation conducted prior to surgery with minimal preparation time.  
1.3.3. Identifying candidate scaffolds 
Given the many current challenges of scaffold design, both biological and translational, the 
identification, optimisation, and translation of the next generation of tissue engineering scaffolds 
would undoubtedly benefit from design tools that could potentially simplify the design process. 
Current biomaterials research traditionally adopts a trial-and-error approach, by altering previous 
design iterations based on in vitro and/or in vivo experimental findings. However repeated 
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experimentation is costly, and time consuming, and often in vitro findings correlate poorly to in vivo 
processes. A beneficial feature in scaffold design would be the ability monitor tissue and scaffold 
performance over the lifetime of the implant. Real-time monitoring of scaffolds, through the 
development of advanced imaging strategies, would enable tissue engineering products to be fine-
tuned using an analytics-based approach to modify design iterations.  
1.3.3.1. Real-time scaffold monitoring 
Currently, magnetic resonance imaging (MRI) 116, positron emission tomography (PET) 117 and 
multiphoton imaging techniques 118 are being trialled to facilitate the tracking of cells within 
scaffolds, however the sensitivity and resolution of these techniques are still not clinically relevant. 
Additionally, these imaging methods often require the introduction of tracer agents into cells and 
have been reported to alter native cell function. For this reason, the imaging modalities of 
bioluminescence have become increasingly popular. Bioluminescence is a form of 
chemiluminescence where photon emission is based on a natural enzymatic biochemical reaction of 
the firefly luciferase enzyme and the luciferin substrate 119. Bioluminescence chemistries have 
become a widely preferred method of quantitative bioanalysis because they can deliver up to 10- to 
1000-fold higher sensitivity than traditional fluorescence assays. Bioluminescent reporters have been 
demonstrated to be stably transfected into practically any cell type and form transgenic mouse strains 
(Figure 11), allowing for imaging in many applications. Furthermore, catalysing bioluminescence 
reactions have been shown to not affect native cell function and can be conducted repeatedly within 
the same cells over time 119, 120. Nevertheless, combining real-time monitoring within tissue 
engineering products by leveraging advanced imaging techniques could potentially simplify the 
scaffold design process by permitting the timelier identification of candidate scaffolds for numerous 
tissue engineering applications.  
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Figure 11 – Transgenic Dual-Reporter Mice 
The strategy of promoter (P)-reporter gene constructs for non-invasive imaging and tracking of cells. 
Encoded reporter proteins include fluorescence proteins and/or bioluminescent enzymes such as 
luciferase. These reporters can be stably transfected into cells or genetically encoded into transgenic 
mice to enable real-time monitoring of cell behaviour. Adapted from 119. 
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1.4. Aims 
There is a considerable deficiency in the development of translational tissue engineering solutions  
for regenerative medicine. In this chapter, we identify inadequacies within the three major 
components of the tissue engineering field that contribute to this deficiency: 
1. Inefficiency of conventional trial-and-error scaffold design processes 
2. Lack of suitable stem cell sources with regard to appropriate sources, numbers, and production 
3. Lack of functionalisation strategies with translational features necessary for patient use 
 
As such, the overarching aims of this thesis will focus on addressing these inadequacies to improve 
the development of translationally relevant tissue engineering solutions for regenerative medicine. 
These include: 
1. Develop a high throughput model for scaffold monitoring to increase the efficiency of scaffold 
design for specific tissue engineering applications. 
2. Investigate novel stem cell sources, with high availability and unlimited renewal, for tissue 
regenerative potential. 
3. Develop scaffold functionalisation strategies that possess both translational features and maintain 
biological function.   
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Chapter 2 
Non-Invasive Tracking of Bone Marrow 
Mononuclear Cells to Injury and Implanted 
Biomaterials 
 
  

1. Introduction
One of the most widely used cell therapies for tissue regenera
tive applications are the transplantation of exogenous bone mar
row mononuclear cells (BM MNC), having been employed as
treatments for various medical conditions including myocardial
infarction [1,2], limb ischemia [3] and traumatic brain injury [4].
The demonstrated tissue regenerative effects of BM MNC are
thought to arise from three major classes of stem cells that exist
within the BM MNC fraction: hematopoietic stem cells (HSCs),
mesenchymal stem cells (MSCs), and endothelial progenitor cells
(EPCs) [5]. However, BM MNC therapy has not yet met
expectations for clinical efficacy due to their poor survival and
engraftment at sites of injury following transplantation [6]. Indeed,
BM MNC function is closely related to their local microenviron
ment niche, which provides both mechanical and chemical cues
that support growth and control differentiation. Importantly,
necrotic tissue at sites of injury are largely void of these cues,
accentuating the challenge of effective therapy [7]. Tissue engi
neering aims to provide artificial microenvironments using bioma
terial scaffolds which better regulate BM MNC behaviour and
survival [8].
The physical and mechanical properties of implanted biomate
rials largely determine the nature of ensuing BM MNC responses.
More closely mimicking the native bone marrow niche in vivo
through tailoring of scaffold parameters including material compo
sition, dynamic control of soluble and surface bound cytokines,
and physicochemical cues is a favoured approach [8]. However,
appropriate mimicry of the extracellular matrix and BM MNC
niche is complex and elusive [7]. In combination with an optimal
blend of mechanical properties and signalling cues, candidate scaf
folds would ideally be available off the shelf to make them clini
cally applicable. The most effective current strategies involve
pre seeding of BM MNC subpopulations onto scaffolds prior to
implantation [9]. However, this severely diminishes the feasibility
of clinical application, due to lengthy time requirements for cell
harvest, culture, and seeding and the high regulatory burden and
cost. Additionally, ex vivo expanded BM MNC subpopulations often
display altered signalling responses, function and phenotype [10].
Together, these shortcomings have prompted investigation into
the cellularization of scaffolds by endogenous recruitment of BM
MNC cells in vivo, an approach known as in situ tissue engineering
[11]. Similarly, approaches combining exogenous BM MNC injec
tions with implanted scaffolds tuned to recruit and engraft BM
MNCs at the site of injury hold significant promise [12].
The model application for in situ tissue engineering strategies
would see biomaterial scaffolds implanted prior to BM MNC injec
tion, serving structural functions in the short term, then facilitate
recruitment of injected BM MNCs in the midterm, and eventually
lead to long term remodelling and being entirely replaced by
new functional tissue. However, as previously mentioned, bioma
terial scaffolds possessing appropriate parameters that favourably
regulate BM MNC function must first be developed. To more read
ily achieve this, in vivo responses of transplanted BM MNC popula
tions towards these biomaterials must first be better understood.
In this study, we developed a model which tracks the temporal
and spatial distribution of intravenously injected BM MNCs,
specifically their homing and engraftment. By measuring the
luciferase induced bioluminescence of these cells in real time,
we were initially able to model injected BM MNC engraftment
responses to injury. In addition we show, through immunohisto
chemical analysis, that engraftment of these cells leads to func
tional effects by elevating the presence of cell phenotypes known
to participate in the native response to injury. Extending the utility
of this model, we further examined its ability to distinguish in vivo
engraftment of injected BM MNC to two model scaffolds. We
demonstrate the bioluminescent curve of each scaffold closely
relates to the ensuing BM MNC engraftment responses towards
the scaffold post implantation. Furthermore, we reveal that differ
ing engraftment responses elicit distinct scaffold remodelling
changes. These findings represent an effective tool to determine,
in real time, biomaterial scaffolds more favourable to injectable
BM MNC therapies.
2. Materials and methods
2.1. Reagents
D luciferin potassium salt was purchased from Cayman Chem
icals (Ann Arbor, MI, USA). Lympholyte M cell separation media
was purchased from Cedarlane Labs (Burlington, ON, CA). Endothe
lial Basal Media (phenol red free) was purchased from Lonza
(Switzerland). Polycaprolactone (PCL) polymer and 1,1,1,3,3,3 hex
afluoro 2 proponal (HFP) solvent were purchased from Sigma
Aldrich (St. Louis, MO, USA). Purified, soluble ovine collagen was
obtained from CollTech (Osborne Park, WA, Australia) and lyophi
lised as previously described [13]. Multiple Stain Solution (MSS)
and JB 4 resin were purchased from Polysciences Inc. (Warrington,
PA, USA).
2.2. FVB L2G mice
Donor firefly luciferase and enhanced green fluorescent protein
(eGFP) co expressing transgenic mouse strains (FVB L2G) were
purchased from Jackson Laboratories (Bar Harbor, ME, USA) (FVB/
NJ Tg(Hspa1a luc, EGFP)2Chco/J, stock no. 012370) [14,15].
Recipient FVB neutral wildtype (WT) mice were purchased from
Australian BioResources (Moss Vale, NSW, Australia).
2.3. Density gradient isolation of BM MNCs
Female FVB L2G mice, aged 7 8 weeks, were anaesthetised
under 2% methoxyfluorane and sacrificed by cervical dislocation.
To collect the bone marrow, tibias and femurs were explanted
and flushed using a 21 gauged needle with sterile PBS. The bone
marrow was then layered on top of Lympholyte M cell separation
media (6 ml per one pair of tibia and femur) and centrifuged at
1250g for 25 min with deceleration off. The resulting buffy coat
was aspirated and washed three times in sterile PBS: 800g for
10 min, 50g for 10 min, and 200g for 10 min. Following the last
wash, the pellet of BM MNC was resuspended in EBM (phenol free)
to desired cell concentrations [6].
2.4. Bioluminescence imaging
D luciferin was reconstituted at a concentration of 40 mg/ml.
Binding of the luciferin substrate to the luciferase enzyme results
in bioluminescence, quantified using the IVIS Series pre clinical
in vivo imaging system apparatus (Perkin Elmer). To induce biolu
minescence, luciferin was given at a total volume of 50 ll for cells
and 200 ll (intra peritoneal) for mice. Bioluminescence was mea
sured in units of radiance (photos/s/cm2/steradian). All biolumi
nescence measurements were calculated within a pre defined
region of interest (ROI). The mean radiance values within an ROI
were recorded. For BM MNC tracking to wounds, the mean radi
ance for each of the four wound ROIs were averaged to give a single
bioluminescence value for each mouse. Bioluminescent profiles
represent average measurements of n = 6 mice per group per time
point. For BM MNC tracking to scaffolds, mean radiance measure
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ments for each scaffold ROI were averaged amongst an n = 6 per
group per timepoint.
2.5. Electrospinning
Polycaprolactone (PCL) was dissolved at 10% (w/v) in 1,1,1,3,3,
3 hexafluoro 2 propanol (HFP). PCL/Collagen blends were made
by dissolving PCL and collagen simultaneously in a 10% (w/v)
HFP solution comprising 90% PCL and 10% collagen. Solutions were
loaded into a syringe and fed through a 0.6 mm diameter needle at
a flow rate of 4 ml/h using a syringe pump. The needle was con
nected to a 20 kV positive power supply and directed at a grounded
parallel plate collector at a distance of 20 cm. Scaffolds were then
cut into circular discs using a 1 cm diameter biopsy punch. Before
implantation, scaffolds were sterilized by UV light for 30 min and
washed three times with and stored in sterile PBS.
2.6. Scaffold characterization
Scaffold surfaces were imaged under a 15 kV scanning electron
microscope (SEM) at 4000x magnification under high vacuum con
ditions. Images were taken for n = 5 scaffolds/group then n = 30
fibers were measured for each sample. For porosity measurements,
scaffolds were embedded in JB 4 resin and cut in 5 mm cross
sections. Cross sections were stained using Multiple Stain Solution
and imaged at 40x magnification. Cross section images were then
converted to 8 bit grayscale and the percentage of white (pores) vs
black (scaffold) were quantified as porosity.
2.7. Mouse subcutaneous homing and engraftment model
Study approval was obtained from Sydney Local Heath District
Animal Welfare Committee (protocol number 2013/050). Experi
ments were conducted in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purpose.
Under 2% methoxyfluorane anaesthesia, mice had their dorsal sur
faces shaved, sterilized with betadine solution, and washed clean
with sterile PBS. Four 1.5 cm incisions (two rows side by side) were
then cut through the skin to create four subcutaneous pockets [16].
For scaffold experiments, PCL or PCL/Collagen scaffolds were
inserted into each incision. Each mouse received two PCL and
two PCL/Collagen scaffolds. The wounds were closed with 6 0 silk
sutures. While still under anaesthesia, mice were then tail vein
injected with 200 ll of isolated BM MNC in EBM (phenol free)
solution (1.5  107 cells/ml). Mice were then allowed to recover
for at least 1 h. Mice underwent IVIS imaging over the course of
21 days in parallel to groups of mice that were sacrificed for skin
wound biopsies alone or together with scaffold implants at defined
histological time points.
2.8. Histology and immunohistochemistry
Skin biopsies were fixed in 4% paraformaldehyde for up to 4 h at
room temperature then changed to 70% ethanol for at least 24 h.
Following dehydration overnight in a tissue processor, biopsies
were embedded in paraffin. Tissue samples were cut into 5 lm
thick transverse sections using a rotary microtome, deparaffinised,
and stained. For histology stains, standard H&E was used to assess
total cell infiltration. For immunohistochemistry analysis, paraffin
sections were stained with primary antibodies including anti
neutrophil elastase (NE) (Abcam, USA) for neutrophils, anti CD68
(Abcam, USA) for macrophages, anti vimentin (Abcam, USA) for
fibroblasts, and anti CD31 (Abcam, USA) for endothelial cells. Flu
orescence microscopy was then used to visualise cell markers
using Alexa Fluor 594 conjugated secondary antibodies. All eGFP
staining was done using cryosectioning. Briefly, tissue was fixed
in 4% paraformaldehyde for up to 4 h at room temperature then
changed to 30% sucrose for at least 24 h. Tissue was then fixed in
optimum cutting temperature (OCT) compound and kept at
80 C until cryosectioning. Samples were sectioned into 40 lm
thick transverse sections and dropped into PBS in order for the
residual O.C.T. to dissolve. Sections were then stained using stan
dard free floating techniques with an FITC conjugated anti GFP
antibody (GeneTex). Both paraffin and cyrosections were then
mounted and coverslipped with DAPI containing mounting media
(VECTASHIELD).
2.9. Quantitative image analysis
Quantification of bioluminescence images was performed using
LivingImage 4.5 (Perkin Elmer) software. Histological and
immunohistochemical sections were imaged using a Zeiss Upright
Olympus fluorescence multi channel microscope, captured with a
Nikon DP Controller 2.2 (Olympus, Japan). Immunohistochemical
and histopathological analysis was done using ImageJ. Briefly,
1  1 mm image fields were taken at the wound or scaffold site.
For neutrophils, macrophages, fibroblasts, and endothelial cells,
positive staining was quantified as individual particles counted
based on a common threshold intensity. All cell types were quan
tified from an n = 6 sections per group per time point.
2.10. Statistical analysis
Data are expressed as mean ± SEM and indicated in figures as
*p < 0.05, **p < 0.01. The data were compared using ANOVA fol
lowed by Bonferoni’s post hoc test using GraphPad Prism version
5.00 (Graphpad Software, San Diego, California) for PC.
3. Results
3.1. Luciferase induced BM MNC bioluminescence
BM MNCs were isolated from the hind limbs of FVB L2G trans
genic mice constitutively expressing the firefly luciferase (Fluc)
and eGFP reporter genes. These cells were visualised through bio
luminescence (IVIS) imaging after administration of the Fluc sub
strate, luciferin (Fig. 1A). The resulting bioluminescence signal
was directly proportional to BM MNC concentration (R2: 0.98)
(Fig. 1B). Therefore, greater bioluminescence measured in a partic
ular region of interest represented higher numbers of these cells in
that area.
3.2. Phenotype characterisation of the BM MNC fraction
Flow cytometry analysis was conducted to characterise the sub
populations present in isolated BM MNCs. Half (51.4 ± 1.9%) of the
BM MNC fraction was comprised of classical immune cell markers
(CD11b+, CD45+). Amongst the stem/progenitor cell phenotypes,
MSCs (CD105+, CD90.1+, CD44+, CD45), HSCs (Sca 1+, c kit+,
CD45+, CD133+), and EPCs (CD31+, CD34+, CD45+) made up
1.2 ± 0.1%, 0.9 ± 0.3%, and 0.6 ± 0.1% of the BM MNC fraction,
respectively (Fig. 2). These results indicate that isolated BM MNC
fractions are a largely heterogeneous cell population, consistent
with previous literature [17].
3.3. Model of BM MNC homing & engraftment tracking
FVB/n mice were given subcutaneous dorsal wounds. Isolated
BM MNCs were then diluted to a working concentration of
1.5  107 cells/ml. This concentration allowed for the delivery of
3  106 cells in a bolus injection volume of 200 ll through the tail
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required to better address the microvascular deficiency, which underlies the development of these wounds and con-
tributes to their persistence and re-occurrence.
Acute wound healing comprises four overlapping stages; haemostasis, inflammation, proliferation and remodelling
[4]. The inflammation and cellular proliferation phases take place from hours to several weeks after an injury and
involve the recruitment of inflammatory cells to the wound site, formation of extracellular matrix (ECM) proteins
and granulation tissue, keratinocyte migration, contraction and wound closure. Angiogenesis, the growth of new
blood vessel networks, is a vital component of these processes and is dependent upon pro-angiogenic growth factors
released by supporting cells, proliferation andmigration of local endothelial cells into thewound bed, and recruitment
of bonemarrow-derived stem cells/endothelial progenitor cells (EPCs) [4-7]. The pathophysiology of chronic wounds
is complex and disordered, but can be largely attributed to persistent inflammation and a lack of adequate tissue
perfusion in the region, exacerbated by failure of ischaemia-mediated angiogenesis in thewound.Collagen deposition
is also reduced in diabetic/PAD patient wounds and the collagen that is present is often glycated, which impairs the
adherence of new keratinocytes to the ECM [8]. Inflammation is also known to be the primary driving force behind
excessive scar formation when a wound does eventually heal [9]. Meanwhile, the inability of EPCs and supporting
cells to form new blood vessel networks to clear necrotic debris and deliver oxygen and nutrients to the granulation
tissue maintains the wound’s inflammatory status. Therapies that can effectively resolve either or both pathological
processes are key to breaking the vicious cycle of failed healing in chronic wounds.
Stem cell therapy is a promising strategy to enhance angiogenesis and promote healing of chronic wounds. Adult
stem and progenitor cells have been studied extensively in animal models of wound healing and appear to exert
their beneficial effects via multiple mechanisms, including recruitment of other cells types, such as keratinocytes,
macrophages and EPCs [10-12]. They have also been shown to produce collagen types I and III, which are critical
for regeneration of the ECM and are the source of structural integrity and tensile strength in the healing tissue [13].
Clinical trials with bonemarrow-derived stem cells are underway and there are a handful of published studies in both
acute (surgical) and chronic (venous insufficiency and diabetic) wounds, which have reported consistent decreases
in wound size, particularly with repeat treatments [14-17]. EPCs and embryonic stem cell derived endothelial cells
have also been tested in animal models and improve wound healing via increased vascularization [18,19]. Indeed, a
common beneficial feature of all stem cell therapies seems to be their pro-angiogenic effect.
Induced pluripotent stem cells (iPSCs) are derived by reprogramming somatic cells, such as dermal fibroblasts.
They have unlimited self-renewal capacity and are therefore an abundant potential source of autologous or donor
matched cells for therapy and may be more clinically translatable than other stem cell types. iPSCs can be differen-
tiated to functional endothelial cells (iPSC-ECs) with high efficiency and reproducibility. We have shown previously
that iPSC-ECs enhance angiogenesis and improve perfusion recovery in a mouse model of peripheral arterial disease
[20,21]. The objective of the current study was to determine whether the pro-angiogenic properties of iPSC-ECs can
be harnessed to promote wound healing. We demonstrate for the first time that iPSC-ECs enhance wound angiogen-
esis and perfusion, promote physiological collagen deposition and accelerate wound closure in a murine excisional
wound healing model. These findings suggest that iPSC-ECs have potential as a treatment for chronic wounds and
support further development of clinical grade iPSC-ECs for therapeutic angiogenesis.
Methods
iPSC reprogramming and differentiation to iPSC-ECs
Human iPSCs were generated via retroviral overexpression of Oct4, Klf4, Sox2, and c-Myc (OKSM) transcription
factors in human dermal fibroblasts derived from healthy subjects. The iPSCs were differentiated to endothelial cells
using previously described methods [20-23] (Supplementary Figure S1). The cells were transduced with a double
fusion reporter construct encoding GFP and firefly luciferase, to enable in vivo fluorescence and bioluminescent
imaging (BLI).
Wound healing procedure
The wounding procedure was adapted from that previously described byGaliano et al. [24] and Dunn et al. [25].Male
NOD/SCID mice were used at 8–10 weeks of age. The operative region of themouse’s back was prepared by removing
the fur with clippers and a light depilatory cream, and two wound outlines were made, using a sterilized 5-mmbiopsy
punch. The skin in the middle of the outline was lifted using serrated forceps and full-thickness wounds were cut and
excised using iris scissors. Silicone splints (approximately 10 mm diameter) were used to prevent wound closure via
contraction. An adhesive was applied sparingly to one side of the splint and the splints were centred over the wounds.
The splints were then secured in place using interrupted 6-0PROLENETM sutures (8805H, Ethicon LLC, San Lorenzo,
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Puerto Rico). After splinting, the mice were scanned with a laser Doppler (MOOR-LMD V192, Moor Instruments,
U.K.) for wound perfusion measurement. They were placed on a heat mat in the prone position and the wound area
was scanned three times per mouse per time point. Doppler scans were performed on alternate days post-wounding,
up to and including day 14. Subsequent to the initial Doppler scan, cell treatments (5 × 105 iPSC-ECs suspended
in vehicle containing a 1:1 ratio of endothelial basal medium to growth factor reduced Matrigel) were injected into
the wounds and the wounds were covered with adhesive OpsiteTM dressings (66000041, Smith & Nephew, London,
U.K.). All wound healing experiments and associated procedures were conducted in accordance with National Health
and Medical Research Council (NHMRC) guidelines for the care and use of animals for scientific purposes and were
approved by the Sydney Local Health District Animal Welfare Committee, Protocol #2014-004A.
BLI
BLI was used for longitudinal tracking of iPSC-EC survival in vivo and was performed with an IVIS Lumina XRMS
and Living Image software (version 4.5, PerkinElmer, Waltham, MA 02451, U.S.A.). The mice were anaesthetized
with 2% isoflurane and d-luciferin (100 μl, 375 mg/kg) was administered by subcutaneous injection in a medial
position immediately inferior to the wound sites. Bioluminescence intensity was calculated as the maximum mean
radiance (photons/second/cm2/steradian) recorded in pre-defined ROI centred over the wounds. BLI was performed
on alternate days post-wounding, up to and including day 14.
Histological analysis of explanted wounds
Wound explants were fixed in 4% paraformaldehyde for up to 4 h at room temperature, then changed to 70% ethanol
for at least 24 h. Paraffin infiltration was performed overnight by an automated tissue processor (Leica TP1020, Leica
Biosystems Nussloch GmbH, Heidelberger Straße 17-19 69226 Nussloch, Germany). The infiltrated samples were
then embedded in paraffin blocks for sectioning. Tissue samples were cut into 5-μm thick transverse sections us-
ing a rotary microtome, deparaffinized, and stained. Milligan’s Trichrome stain was performed to visualize colla-
gen content. For immunohistochemistry analysis, paraffin sections were stained using immunohistochemistry tech-
niques with primary antibodies anti-CD31 (Abcam, U.S.A.) for endothelial cells and anti-CD68 (Abcam, U.S.A.)
for macrophages. Fluorescence microscopy was then used to visualize cell markers using Alexa Fluor 594 conjugated
secondary antibodies. Anti-GFP stainingwas done using cryosectioning. Briefly, tissuewas fixed in 4% paraformalde-
hyde for up to 4 h at room temperature then changed to 30% sucrose for at least 24 h. Tissue was then fixed in op-
timum cutting temperature (OCT) compound and kept at −80◦C until cryosectioning. Samples were sectioned into
40-μm thick transverse sections and dropped into PBS in order for the residual O.C.T. to dissolve. Sections were then
stained using standard free-floating techniques with a FITC-conjugated anti-GFP antibody (GeneTex). Both paraffin
and cyrosections were then mounted and coverslipped with DAPI-containing mounting media (Vectashield, Vector
Laboratories Inc., CA, U.S.A.).
Analysis of host angiogenic gene expression in wounds
Total RNA was isolated from explanted control and iPSC-EC treated wounds with TRIzol reagent. Real-time quanti-
tative PCR analysis was performed to evaluate the expression of murine vascular endothelial cadherin (VE-cadherin;
sense: 5′-TCCTCTGCATCCTCACTATCACA-3′, antisense: 5′-GTAAGTGACCAACTGCTCGTGAAT-3′) ,
vascular endothelial growth factor receptor-1 (Flt-1; sense: 5′-GAGGAGGATGAGGGTGTCTATAGGT-3′,
antisense: 5′- GTGATCAGCTCCAGGTTTGACTT-3′), vascular endothelial growth factor receptor-2 (KDR;
sense 5′-CCCTGCTGTGGTCTCACTAC-3′, antisense: 5′-CAAAGCATTGCCCATTCGAT-3′), platelet en-
dothelial cell adhesion molecule (PECAM-1; sense: 5′-GAGCCCAATCACGTTTCAGTTT-3′, antisense:
5′-TCCTTCCTGCTTCTTGCTAGCT-3′), tyrosine kinase with Ig-like and EGF-like domains-1 (Tie-1; sense: 5′-
CAAGGTCACACACACGGTGAA-3′, antisense: 5′-GCCAGTCTAGGGTATTGAAGTAGGA-3′), and vascular en-
dothelial growth factor (VEGF; sense: 5′-TGCCAAGTGGTCCCAG-3′, antisense: 5′-GTGAGGTCTTGATCCG-3′).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH; sense: 5′-GGGGCTCTCTGCTCCTCCCTGT-3′, antisense:
5′-CGGCCAAATCCGTTCACACCGA-3′) was used as a loading control. Relative gene expression was calculated as
fold change compared with paired control wounds.
Quantiﬁcative analysis of bioluminescence and histological images
Quantification of bioluminescence images was performed using LivingImage 4.5 (PerkinElmer) software. Histolog-
ical and immunohistochemical sections were imaged using a Zeiss Upright Olympus fluorescence multichannel mi-
croscope, captured with a Nikon DP Controller 2.2 (Olympus, Japan). Immunohistochemical and histopathological
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 1. iPSC-EC engraftment in wounds
iIPSC-ECs were transduced with a double fusion reporter construct encoding GFP for fluorescence imaging and firefly luciferase
for BLI. (A) Representative IVIS images, showing bioluminescent signal present in iPSC-EC-treated wounds (right) on days 0, 6 and
14 post-wounding. (B) Declining bioluminescent signal in wounds over time, relative to control wound background signal. (C) GFP
staining (green) with DAPI nuclear stain (blue) in control and iPSC-EC treated wounds at on days 7 and 14 post-wounding (n=6 per
treatment group).
analyses were done using ImageJ. Briefly, regions of interest (ROIs) were drawn around the wound site. For endothe-
lial cells and fibroblasts, positive stainingwas quantified as individual particles counted based on a common threshold
intensity. All cell types were quantified from n=6 sections per group per time point.
Statistics
Data are expressed as mean +− S.E.M. and indicated in figures as *P<0.05, **P<0.01. The data were compared using
paired Student’s t tests followed by Bonferoni’s post-hoc test using GraphPad Prism version 5.00 (GraphPad Software,
San Diego, CA) for PC. IPSC-EC experimental samples were paired to control wounds within the same mouse.
Results
Engraftment of iPSC-ECs within wounds decreases following
transplantation
BLI was used to quantify the levels of iPSC-EC engraftment within wounds over time. Transfection of iPSC-ECs
with a dual-report construct containing both the enhanced GFP (eGFP) and the firefly luciferase enzyme enabled
visualization and quantification of transplanted iPSC-ECs. Intramuscular injection of d-luciferin substrate catalysed
a bioluminescent reaction through the firefly luciferase enzyme within viable iPSC-ECs that could be visualized and
quantified using the IVIS apparatus (Figure 1A). Bioluminescence quantification over 14 days showed that iPSC-EC
presence in wounds decreases steadily over time (Day 0: 1.39 × 107 +− 5.61 × 106 compared with Day 14: 4.04 ×
4 c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 2. iPSC-EC treatment increases expression of pro-angiogenic genes
qPCR analysis of wound mRNA revealed a significant up-regulation of PECAM (CD31) and endothelial cell receptor, Tie-1, ex-
pression in iPSC-EC wounds on day 7 post-wounding. This was resolved by day 14. No significant differences in endothelial cell
surface marker VE-cadherin (CD144), VEGF, VEGF receptor 1 (Flt1) or VEGF receptor 2 (KDR) expression were measured (*P<0.05
compared with controls, n=6 per treatment group).
104 +− 1.53 × 104 photons/cm2/s/steradian). The largest decrease in bioluminescence occurred between days 2 and
4 (Day 2: 8.36 × 106 +− 5.44 × 106 compared with Day 4: 7.66 × 105 +− 3.65 × 105 photons/cm2/s/steradian, Figure
1B). Immunohistochemistry staining of the eGFPmarker identified iPSC-ECs engrafted within the wound site at day
7, and a smaller proportion remaining at 14 days post-transplantation (Figure 1C).
Engraftment of iPSC-ECs correlates with up-regulation of host
angiogenic gene expression
Functional angiogenesis is a complex process regulated by numerous cells types and growth factors. Ischaemic/injured
tissues undergoing revascularization processes are often identified by the up-regulation of key angiogenic genes in-
cluding VE-cadherin, VEGF, Flt-1, KDR, PECAM, and Tie-1. Wounds were explanted at days 7 and 14 for qPCR
analysis to determine levels of these classical angiogenic genes. Increasing trends were observed in the expression of
VE-cadherin, Flt-1, and KDR in iPSC-EC treated wounds when compared with control wounds at both time points,
however no statistical significance was obtained. At day 7, PECAM and Tie-1 genes were found to be significantly
u-regulated by 350 +− 89 and 534 +− 134% in iPSC-EC treated wounds compared with control wounds (Figure 2).
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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Figure 3. iPSC-EC treatment increases vascular density and wound perfusion
(A) Representative laser Doppler images, showing perfusion in control and iPSC-EC treated wounds on days 0, 4, 8 and 18 post–
wounding. (B) Wound perfusion in iPSC-EC treated wounds, relative to their respective control wounds. Increased perfusion in
iPSC-EC treated wounds was most pronounced during the first week of healing. (C) Representative photomicrographs of wounds,
showing increased neo-vessel formation in iPSC-EC wounds relative to controls. (D) Capillary density, as measured by CD31+
staining, was significantly increased in iPSC-EC wounds at both early and late time points (*P<0.05, n=6 per treatment group).
At day 14, VEGF expression was significantly up-regulated by 12 +− 4% in iPSC-EC treated wounds compared with
controls (Figure 2).
Wounds treated with iPSC-ECs exhibit increased angiogenesis
The anatomical hallmarks of angiogenesis include increased blood perfusion and high density of neo-capillary forma-
tion. Non-invasive IR laser Doppler imaging was conducted at the wound sites over 14 days to visualize and quantify
levels of blood perfusion for the duration of wound healing (Figure 3A). Laser Doppler analysis revealed a maximum
of two-fold increase inwound perfusion comparedwith controlwithin the first 4 days following treatment in iPSC-EC
treated wounds compared with control (Figure 3B). This gradually decreased back to baseline control wound perfu-
sion levels by day 10. The subcutaneous layers of iPSC-EC treated, and control wounds were photographed following
explant. A higher density of observable blood vessels was observed in iPSC-EC treated wounds compared with con-
trol (Figure 3C). To assess neo-capillary formation, cross-sections of wound explants were stained using the CD31
endothelial cell marker. At day 7, iPSC-EC treated wounds showed a 16-fold increase in capillary density compared
with control wounds, which decreased to a four-fold increase by day 14 (Figure 3D).
iPSC-EC treatment enhances the native wound healing process
Native wound healing processes involve numerous cell phenotypes responsible for rebuilding the tissue architecture
necessary for cell repopulation. Of these cell types, fibroblasts are largely implicated as essential matrix remodelling
cells which facilitate neo-collagen deposition as a temporary matrix for cell growth and tissue regeneration. Using
trichrome staining, wound cross-sections were quantified for levels of collagen deposition. iPSC-EC treated wounds
showed a 20 +− 4% increase in collagen deposition at day 14 compared with control wounds (Figure 4B). Similar
trends were observed with macrophage infiltration. At day 14, iPSC-EC treated wounds showed a 174 +− 6% increase
in macrophage numbers compared with control wounds (Figure 5). The functional outcomes of wound healing were
measured by taking three diameter measurements of wounds over 14 days and represented as percentage of total
wound closure. iPSC-EC treated wounds show accelerated wound closure from day 2, which was significant on days
4 and 10 post-wounding and achieved complete wound closure 4 days earlier than control wounds (Figure 4A).
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Figure 4. iPSC-EC treatment increases collagen deposition and accelerates wound closure
(A) Representative photomicrographs, showing progressive wound closure over a 14-day period. Rate of closure was significantly
increased in iPSC-EC treated wounds compared with controls. (B) Milligan’s Trichrome staining for collagen content. No differences
were observed on day 7; by day 14 iPSC-EC treated wounds had significantly higher collagen content (*P<0.05, **P<0.01, n=6
per treatment group).
Figure 5. iPSC-EC treatment increases macrophage inﬁltration
(A) Anti-CD68 staining for macrophage infiltration. No differences were observed on day 7; by day 14 iPSC-EC treated wounds had
significantly macrophage infiltration (*P<0.05, n=6 per treatment group).
Discussion
Chronic wounds and ulcers persist in a state of pathological inflammation, characterized by increased proteolytic ac-
tivity, increased production of reactive oxygen species (ROS), senescent or dysfunctional fibroblasts, neutrophils and
c© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution
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macrophages, and reduced pro-angiogenic growth factors and cytokines [4,7]. The aetiology of chronic wound for-
mation in diabetes and peripheral arterial disease is multifactorial, but a major cause is underlying vasculopathy and
diminished angiogenesis. The angiogenic response to ischaemia declines naturally with age and is further impaired in
patients with vascular disease, who have reduced number and functionality of circulating EPCs [26-30]. The impor-
tance of angiogenesis in wound healing has been highlighted by interventional studies, which have shown that topical
application of pro-angiogenic factors, such as VEGF or bFGF, is beneficial in accelerating diabetic wound healing in
mice, while neutralizing them has the opposite effect [31-33]. However, clinical trials using single growth factors to
boost angiogenesis have been largely unsuccessful, which likely reflects the complex regulation of angiogenesis in
vivo and the need for a multifactorial approach [34].
Bone marrow and adipose tissue derived MSCs and EPCs have been in development for therapeutic angiogene-
sis for the past two decades, and have shown promise in promoting wound healing , however limited availability of
healthy adult stem cells, and invasive aspiration procedures have tempered their use. iPSCs and their derivatives have
several advantages, such as their relatively abundant supply, their non-controversial origins and the lack of immuno-
genicity if used for autologous transplantation [35]. Furthermore, the development of iPSC banking, the creation
of multiple iPSC lines representing commonly present HLA allele combinations, means that patients could receive
non-autologous cells without evoking an immune rejection, increasing the throughput while simultaneously reducing
the time, cost and invasiveness of pluripotent cell therapies [36].
Here, we demonstrate the pro-angiogenic and wound healing capabilities of iPSC-ECs in a murine excisional
wound model. Angiogenesis is vital for the formation and maintenance of granulation tissue in the first 2–4 days
post-wounding. Neo-vessel formation typically begins around this time, peaking around day 7 before giving way to
remodelling and maturation of the newly formed vasculature. We observed significantly accelerated wound closure
in iPSC-EC treated wounds, as well as increased wound perfusion in the first week of healing, which was associated
with a significant increase in endothelial cell surface marker PECAM-1 (CD31) staining in the wounds at both 7 and
14 days post-wounding. Consistent with previously described temporal patterns of angiogenesis in wound healing,
absolute laserDoppler perfusionmeasurements decreased in both groups during the secondweek, approaching those
of the surrounding healthy skin, as new dermis progressively covered exposed capillaries at the wound surface. Ex-
pression of PECAM-1 and Tie-1mRNAwas significantly up-regulated in iPSC-EC wounds on day 7 but was similar
to expression in control wounds by day 14. Tie 1 is an endothelial cell specific orphan receptor, which has been shown
to promote sprouting angiogenesis via regulation of Tie 2 receptor signalling [37].
iPSC-EC treatment also increased wound collagen deposition; sections from wounds treated with iPSC-ECs had
significantly higher collagen content than the control wounds on day 14. Collagen deposition is vital for healthy
wound healing, but the implication of increased collagen depends on the stage of healing as well as the types of colla-
gen present; in the proliferative stage of healing collagen provides amatrix to support inflammatory and vascular cells
as well as forming a stronger barrier than the fibrin clot [38]. In the late stages (remodelling), a reduction in collagen
content is desirable to limit scarring. Collagen deposition begins within the first 24 h after wounding and peaks be-
tween 1 and 3 weeks later, depending on the wound site and size. As these wounds were still actively healing and in the
proliferative phase at day 14, the observation of increased collagen ismost likely indicative of amore advanced stage of
healing compared with the controls, rather than excessive scarring. We also observed increased macrophage infiltra-
tion in iPSC-EC treated wounds at day 14 post-wounding, as evidenced by significantly increased CD68+ staining. In
normal wound healing, macrophage infiltration peaks during the inflammatory phase (day 1–3 post-wounding) be-
fore subsiding. We observed no difference in CD68+ staining between control and iPSC-EC treated wounds at 7 days
post-wounding. However, by day 14 iPSC-EC treated wounds had significantly greater CD68+ staining compared
with their respective controls, suggesting sustained macrophage activity. This observation may be due to increased
recruitment of macrophages in response to iPSC-ECs.
Poor cell survival and engraftment remains a major limitation to the long-term efficacy of cell therapies and there-
fore their suitability for clinical use. Most cells are lost within the first 48 h after administration, due to poor retention
and cell death due to excessive inflammation, ischaemia or anoikis, the programmed death that occurs in endothelial
cells and other anchorage-dependent cell types when they lose their interaction with ECM [39]. Very few previous
wound healing studies included longitudinal tracking of the implanted cells to determine their eventual fate and those
that did reported low rates of engraftment [40,41].We used a firefly luciferase reporter gene construct andBLI for lon-
gitudinal tracking of iPSC-EC survival in vivo and although iPSC-EC fluorescent and bioluminescent signal was still
detectable in the wounds 14 days post-treatment, we observed a substantial and progressive decline over the 2-week
period. These data are consistent with previous in vivo survival of iPSC-ECs and suggest that the pro-angiogenic and
pro-healing effects of our cells were primarily mediated via secretion of paracrine factors rather than engraftment or
proliferation of the cells themselves [42]. Despite low rates of engraftment, stem cell treatments consistently evoke a
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beneficial response. This suggests that even small increases in retention could translate to sizeable improvements in
tissue regeneration and long-term recovery and we are conducting further studies seeding iPSC-ECs on biomaterial
scaffolds to determine if this can increase their in vivo longevity and potentiate their beneficial effects.
Limitations
NOD/SCID mice are widely used in human haematopoietic cell studies and are an ideal strain for human cell trans-
plantation because they lack functionalB andT lymphocytes, lack the ability tomount an antibody-mediated response
and additional deficiencies in their innate immune system allow for increased donor cell engraftment [43]. However,
the blunted immune response to the cells creates a somewhat artificial environment in comparison with the situation
in an immune competent organism. That being said, it is not possible to conduct pre-clinical, mechanistic investi-
gations using human cells in other species without modulating the immune response. It is anticipated that the use
of autologous or donor matched cells clinically would also mitigate the effects of immune rejection of the engrafted
cells by the recipient, therefore we considered the NOD/SCID mouse to be the most suitable and appropriate model
for these studies. It should also be noted that these mice are neither aged nor diabetic, so most innate wound healing
capabilities are intact. This means that treatment effects are more difficult to detect, thus we anticipate an even more
pronounced improvement after iPSC-EC treatment if we were able to use these cells in such a model.
Finally, we acknowledge that the iPSC-ECs used in the present study were differentiated from iPSCs that were
generated using integrating viral vectors. These cells may not be suitable for use in a clinical setting because of the
possibility of foreign DNA integrating into the host genome. However, the development of reprogramming protocols
using small molecules means that iPSC-ECs for clinical applications can be generated without the use of viral vectors.
Conclusion
In the present study, we have demonstrated for the first time that human iPSC-ECs have pro-angiogenic functionality
in wound healing, promote fibroblast infiltration and collagen deposition and accelerate wound closure. Longitudinal
tracking of iPSC-ECs in vivo revealed a progressive decline in surviving iPSC-ECs over time, indicating that the cells
are acting primarily through short-term paracrine effects. These findings have provoked further studies optimising
iPSC-EC delivery to improve in vivo survival and engraftment rates, and alsomake a strong case for the development
of clinical grade iPSCs and their derivatives for therapeutic angiogenesis in patients with vascular diseases.
Perspectives
(i) Ischaemia-mediated angiogenesis is impaired in patients with cardiovascular disease and diabetes,
which leads to the development of intractable wounds and ulcers.
(ii) Here, we show that human iPSC-derived endothelial cells (iPSC-ECs) promote angiogenesis, in-
crease collagen deposition and accelerate healing in a murine wound healing model.
(iii) Further development of human iPSC-ECs for therapeutic angiogenesis is a promising strategy to
reduce the burden of chronic wounds in patients with peripheral arterial disease and diabetes.
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Chapter 4 
Integration of Induced Pluripotent Stem Cell 
Derived Endothelial Cells with 
Polycaprolactone/Gelatin-Based Electrospun 
Scaffolds for Enhanced Therapeutic 
Angiogenesis 
  

Background
Ischemic injury is one of the key biological events
underlying the tissue pathology of some of the most de-
bilitating diseases, including myocardial infarction, acute
kidney failure, and stroke [1]. Ischemia, caused by the
complete or even partial occlusion of the blood vessel
network in the affected organ, results in drastic levels of
nutrient and oxygen depletion (hypoxia) as well as inad-
equate removal of metabolic waste. Without timely and
robust intervention, ischemia progresses to tissue necro-
sis and, in highly sensitive organs such as the brain or
heart, can lead to immediate death [2, 3]. Responding to
tissue ischemia, the body activates innate healing mecha-
nisms that attempt to restore blood flow through the
formation of new blood vessel networks, a process
known as angiogenesis. However, these native revascu-
larization systems often occur too slowly and/or are in-
adequate in magnitude to overcome large-scale ischemic
injury [4]. This shortcoming has inspired a field of
regenerative medicine that aims to augment and control
the host angiogenic response to revascularize ischemic
tissue, known as therapeutic angiogenesis.
While individual growth factors and genes regulating
angiogenesis have been well characterized, their transla-
tion to therapeutic angiogenesis in vivo has been
underwhelming, demonstrated by several inconclusive or
negative clinical trials [5, 6]. For example, single agents
such as vascular endothelial growth factor (VEGF) aiming
to promote increased peripheral angiogenesis are promis-
ing in preclinical studies, but perform poorly in human
trials [7]. As a result, it has become increasingly accepted
that modulation of angiogenesis involves the activation of
a complex network of events not readily addressed by a
single growth factor or gene therapy. Thought to repre-
sent a more extensive and comprehensive control over
angiogenesis, stem/progenitor cell-based therapy has
gained attention due to the cells’ intrinsic characteristics
as hypoxia-responsive multiparacrine release vehicles.
While stem cell therapy has traditionally been plagued by
inadequate cell numbers and ethical concerns regarding
their origin, in recent years the advent of induced pluripo-
tent stem cells (iPSCs) has overcome some of these bar-
riers [8]. iPSCs can be generated from any somatic cell
and possess unlimited self-renewal and differentiation po-
tential [8]. Of the numerous iPSC-derived cell phenotypes
extensively studied for proangiogenic function, iPSC-
derived endothelial cells (iPSC-ECs) appear to be most
promising for therapeutic angiogenesis [9–11]. However,
translational challenges for iPSC-ECs common to trad-
itional stem cell therapy remain; in particular, low levels of
in-vivo engraftment and short-term viability [12]. iPSC-
ECs fail to integrate with the host tissue and gradually die
after delivery [9, 10, 13], highlighting an essential need for
engraftment strategies capable of extending their in-vivo
lifetime and potentially augmenting their proangiogenic
function.
Synthetic biomaterial scaffolds have made a tremen-
dous impact in regenerative medicine by allowing
researchers to provide functional platforms containing
the biophysical and chemical cues necessary to sustain
stem cell behavior and function [14] that are often
absent at sites of ischemic injury and necrotic tissue.
The employment of biomaterial scaffolds to enhance en-
graftment of iPSC-ECs in vivo is a promising approach
to improve therapeutic angiogenesis. However, literature
surrounding iPSC-ECs combined with biomaterial
scaffolds in vivo is limited, with only a few publications
to date investigating this concept [15, 16]. While demon-
strating enhanced angiogenic effects, these studies are
conducted in immunodeficient mice that do not represent
native engraftment conditions following exogenous cell
injections. Additionally, the functional mechanisms under-
lying scaffold-mediated enhancement of iPSC-EC proan-
giogenic function in vivo have not yet been defined.
Insight into these mechanisms is important for future
optimization of combined iPSC-EC scaffold strategies and
for defining the practical guidelines necessary for their
improved translation.
In this study, we conduct a comprehensive analysis of
electrospun polycaprolactone (PCL)/gelatin scaffolds and
their potential to enhance the engraftment and proan-
giogenic function of iPSC-ECs in vitro and in vivo.
Through tailoring of material composition and structural
properties, we identify candidate scaffolds best able to
support iPSC-EC growth and function in vitro. Using
these scaffolds as engraftment platforms, we assess their
potential to augment the proangiogenic effects of iPSC-
ECs following implantation in vivo. Through gene
expression and immunohistochemical analysis, we
identify some of the key drivers of scaffold-mediated
enhancement of iPSC-EC angiogenic function, while de-
fining important benchmarks of scaffold performance
that relate to these effects. The findings of this study
provide mechanistic knowledge essential to the future
development of optimized therapies combining iPSC-
ECs with biomaterial scaffolds, which may ultimately
improve the translation of iPSC-ECs for therapeutic
angiogenesis.
Methods
Reagents
D-Luciferin potassium salt was purchased from Cayman
Chemicals (Ann Arbor, MI, USA). Lympholyte®-M cell
separation medium was purchased from Cedarlane Labs
(Burlington, ON, CA). Endothelial Basal Medium (phenol
red free) was purchased from Lonza (Switzerland). Polyca-
prolactone (PCL) polymer, gelatin, and 1,1,1,3,3,3-hexa-
fluoro-2-proponal (HFP) solvent were purchased from
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Sigma-Aldrich (St. Louis, MO, USA). Purified, soluble
ovine collagen was obtained from CollTech (Osborne
Park, WA, Australia) and lyophilized as described previ-
ously. Multiple Stain Solution (MSS) and JB-4 resin were
purchased from Polysciences Inc. (Warrington, PA, USA).
Electrospinning
PCL and gelatin were dissolved at a total of 10% (w/v) in
HFP in varying ratios. Solutions were loaded into a syr-
inge and fed through a 0.6-mm-diameter needle at a
flow rate of either 8 ml/h or 16 ml/h using a syringe
pump. The needle was connected to a 20-kV positive
power supply and directed at a grounded parallel plate
collector at a distance of 20 cm. Scaffolds were then cut
into circular discs using a 6-mm-diameter biopsy punch.
Before cell seeding and implantation, scaffolds were ster-
ilized by UV light for 30 min and washed three times
with and stored in sterile PBS.
Scaffold characterization
Scaffold surfaces were imaged under a 15-kV scanning
electron microscope at 4000× magnification under high
vacuum conditions. Images were taken for n = 5 scaffolds/
group and then n = 100 fibers were measured for each
sample. For porosity measurements, scaffolds were em-
bedded in JB-4 resin and cut into 5-μm cross-sections.
The cross-sections were stained using Multiple Stain
Solution and imaged at 40× magnification. Cross-section
images were then converted to 8-bit grayscale and the per-
centage of white (pores) vs black (scaffold) was quantified
as porosity. For scaffold wetting experiments, scaffolds
were soaked in PBS for 7 days at 37 °C. Scaffolds were
then completely dried overnight in a fume hood at RT
prior to scanning electron microscopy (SEM) imaging.
Mechanical testing of the electrospun scaffolds was
performed on an Instron Tensile Machine (Instron
5543). Briefly, scaffolds were cut into strips of 0.5 cm ×
3.5 cm and clamped into the Instron. A constant pull of
3 mm/min was applied and the force measured by a 50-
N load cell. Wet samples were incubated in PBS at 37 °C
for 1 h and dried prior to measurement. The elastic
modulus was obtained from the linear region of the
stress/strain curve. Ultimate tensile strength was defined
as the maximum force at break.
Degradation testing of electrospun scaffolds was per-
formed by immersing scaffold samples in a 1 U/ml Pro-
tease XIV (Sigma) solution at 37 °C for 4 days. Samples
were preweighed prior to immersion and were allowed
to dry prior to reweighing. Degradation was expressed as
the percentage of initial weight remaining per day.
iPSC-EC derivation and culture
iPSC-ECs were fully differentiated and characterized, as
described previously [17], prior to use in experiments.
Briefly, iPSCs were generated via retroviral overexpres-
sion of Oct4, SOX2, KLF4, and c-Myc in adult human
dermal fibroblasts and differentiated into endothelial
cells using previously described methods [9, 18]. On day
14 of differentiation, iPSC-ECs were purified using FACS
to sort for CD31+ cells (Anti-human CD31-PE;
eBioscience Inc., San Diego, CA, USA) as described pre-
viously [19]. iPSC-ECs were also stably transfected with
a reporter expression system encoding the firefly lucifer-
ase enzyme as an imaging modality. iPSC-ECs were
cultured in EGM-2MV media (CC3202; Lonza Group
Ltd) and seeded on PCL/gelatin scaffolds at a concentra-
tion of 1 × 105 cells/scaffold in a total media volume of
200 μl. After 24 h, scaffolds were placed into fresh
EGM-2MV and the media changed every other day for 7
days (Fig. 1b). For hypoxia experiments, iPSC-ECs were
cultured in 1% O2 for 24 h prior to RNA extraction and
subsequent qPCR analysis. Prior to implantation, iPSC-
EC-seeded scaffolds and iPSC-ECs alone were washed
and suspended in basal EGM to remove all endothelial
growth factors from the media.
Angiogenic gene expression in vitro
Quantitative PCR was performed using iQ SYBR-Green
Supermix and the iCycler Real-time PCR Detection System
(Bio-Rad). Gene expression was calculated using primers
for vascular endothelial growth factor (VEGF) (forward, 5′-
TGCCAAGTGGTCCCAG–3′; reverse, 5′-GTGAGGTCT
TGATCCG-3′), epidermal growth factor (EGF) (forward,
5′-GAGGAGCACGGGAAAAGAA-3′; reverse, 5′-CCGG
AGCTCCTTCACATATT-3′), and placental growth factor
(PlGF) (forward, 5′-GTTCAGCCCATCCTGTGTCT-3′; re
verse, 5′-TTAGGAGCTGCATGGTGACA-3′), with B2M
as a housekeeping gene.
Mouse subcutaneous implantation
Study approval was obtained from Sydney Local Heath
District Animal Welfare Committee (protocol number
2013/050). Experiments were conducted in accordance
with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purpose. Under 2% meth-
oxyfluorane anesthesia, wild-type FVB/n mice had their
dorsal surfaces shaved, sterilized with betadine solution,
and washed clean with sterile PBS. Four 1.5-cm incisions
(two rows side by side) were then cut through the skin
to create four subcutaneous pockets [20]. Within each
wound, control EBM media, iPSC-ECs, iPSC-EC-seeded
scaffolds, or scaffold alone were transplanted. The
wounds were closed with 6–0 silk sutures. Mice were
then allowed to recover for at least 1 h. Mice underwent
IVIS imaging over the course of 9 days when biolumin-
escent signals from iPSC-ECs were no longer observed.
Skin wound biopsies were taken at defined histological
time points.
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Bioluminescence imaging
D-Luciferin was reconstituted at a concentration of 40
mg/ml. Binding of the luciferin substrate to the lucifer-
ase enzyme results in bioluminescence, quantified using
the IVIS Series preclinical in-vivo imaging system appar-
atus (Perkin Elmer). To induce bioluminescence, lucif-
erin was given at a total volume of 100 μl through
intramuscular administration at the implantation site.
Bioluminescence was measured in units of radiance
(photons/s/cm2/sr). All bioluminescence measurements
were calculated as mean radiance within a predefined re-
gion of interest (ROI). Mean radiance measurements for
each ROI were averaged amongst n = 5 per group using
repeated measurement of the same subjects over time.
Perfusion Doppler imaging and analysis
Post surgery, perfusion at the implantation site was mea-
sured by laser Doppler MOOR-LMD V192 (Moor Instru-
ments, UK). Mice were anesthetized prior to imaging and
the anesthetic removed during imaging. Three repeat
Doppler measurements were taken after removal of the
anesthetic to prevent perfusion data being affected by vari-
ations in depth of anesthesia. Doppler recordings were
taken of the entire mouse back in a scan area of 6 cm × 8
cm at a scan rate of 10 px/s. Doppler measurements (n =
5 per group) were quantified by drawing equal areas with
the surgical wound of the implantation site located in the
middle of the quantification area.
Histology and immunohistochemistry
Histology and immunohistochemistry analysis was con-
ducted as described previously [20]. Briefly, for histology
stains, standard H&E was used to assess total cell infil-
tration. For immunohistochemistry analysis, sections
were stained with primary antibodies including anti-
VEGFA (Abcam, USA) for vascular endothelial growth
factor expression, anti-PlGF (Abcam, USA) for placental
growth factor expression, anti-NE (neutrophil elastase)
(Abcam, USA) for neutrophils, anti-CD68 (Abcam,
USA) for macrophages, anti-CD31 (Abcam, USA) for
endothelial cells, anti-vimentin (Abcam, USA) for fibro-
blasts, and anti-SMC-α actin (Abcam, USA) for smooth
muscle cells. Fluorescence microscopy was then used to
visualize cell markers using Alexa Fluor 594-conjugated
secondary antibodies. Sections were mounted with
DAPI-containing mounting media (VECTASHIELD).
Quantitative image analysis
Quantification of bioluminescence images was per-
formed using LivingImage 4.5 (Perkin Elmer) software.
Histological and immunohistochemical sections were
imaged using a Zeiss Upright Olympus fluorescence
Fig. 1 a Schematic of iPSC EC differentiation and characterization. b iPSC EC seeding protocol on electrospun scaffolds. c SEM images of PCL/gelatin
scaffolds at varying flow rates and PCL/gelatin blends; quantification of fiber thickness (inset), scale bar represents 50 μm. ****p < 0.0001. n = 5 scaffolds/
group and n = 100 fibers/scaffold. PCL polycaprolactone, PG73 PCL/gelatin (70:30 ratio), PG55 PCL/gelatin (50:50 ratio)
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multichannel microscope, captured with a Nikon DP
Controller 2.2 (Olympus, Japan). Immunohistochemical
and histopathological analysis was done using ImageJ.
For immunohistochemical analysis, marker expression
was expressed as the positive stained area determined by
a common threshold intensity divided by the tissue area
of measurement. All markers were quantified from n = 6
sections per group per time point.
Statistical analysis
Data are expressed as mean ± SEM and statistical sig-
nificance indicated as either p < 0.05, p < 0.01, p <
0.001, or p < 0.0001. The data were compared using
one-way ANOVA followed by Bonferroni’s post-hoc test
or two-way ANOVA followed by Tukey’s post-hoc test
using GraphPad Prism version 5.00 (GraphPad Software,
San Diego, CA, USA) for PC.
Results
Scaffold characterization
Solutions of pure PCL and blends of PCL and gelatin at
ratios of 70:30 (PG73) and 50:50 (PG55) were electro-
spun at low (8 ml/h) and high (16 ml/h) flow rates. SEM
analysis of scaffold surfaces showed that the fiber width
increased at high flow rates in gelatin-containing blends
only (1.35 ± 0.53 vs 2.63 ± 1.04 μm in PG73, p < 0.0001;
0.98 ± 0.38 vs 3.95 ± 2.27 μm in PG55, p < 0.0001)
(Fig. 1b). High flow rate fibers were largest in PG55
blends followed by PG73 (3.95 ± 2.27 vs 2.63 ± 1.04 μm,
p < 0.0001; Fig. 1b). However, PG55 scaffolds had a lar-
ger distribution of fiber widths compared to PG73. SEM
analysis of high flow rate PG73 and PG55 scaffolds after
7 days of wetting in PBS showed that PG55 fibers ap-
peared to be more structurally compromised compared
to PG73 fibers, indicated by a loss of fiber morphology
(Additional file 1: Figure S1A).
To further examine the physical stability of PG73 scaf-
folds, mechanical testing and degradation experiments
were conducted. Mechanical testing of PG73 scaffolds
showed that wetting of the scaffold did not compromise
structural integrity, indicated by no significant changes
in ultimate tensile strength (UTS) and Young’s modulus
before and after wetting (Additional file 2: Figure S2B,
C). Additionally, under accelerated degradation condi-
tions in a Protease XIV solution at 37 °C for 4 days,
PG73 scaffolds showed similar degradation profiles as
pure PCL (Additional file 2: Figure S2D).
Cross-sectional imaging revealed the internal structure
of scaffolds, allowing for an estimation of pore size. No
significant differences were observed between scaffold
groups; however, pore size tended to be reduced with
both higher flow rates and increasing gelatin content
(Additional file 1: Figure S1B).
iPSC-EC growth and phenotype on scaffolds
iPSC-ECs were seeded on scaffolds and cell growth was
quantified using a transfected bioluminescence reporter.
Generation of a standard curve demonstrated a linear
correlation of bioluminescence intensity to iPSC-EC num-
ber (Fig. 2a). The detectable range of iPSC-EC biolumines-
cence was found to be between 1 × 103 and 1 × 106 cells/
well (Additional file 3: Figure S3). Concentrations of iPSC-
ECs less than 1 × 103 cells/well were not significantly
different from background signals, while those greater
than 1 × 106 cells/well saturated the bioluminescence
reading capacity of the IVIS imaging apparatus.
At day 3 in culture, the highest cell numbers were ob-
served on PG73 and PG55 scaffolds at high flow rates (1.44
± 0.45 and 1.45 ± 0.28 × 105 cells, respectively; Fig. 2b). By
day 7, these conditions were both significantly increased
compared to all scaffold groups (3.12 ± 0.73 and 2.69 ± 1.02
× 105 cells, respectively, p < 0.001 and p < 0.01; Fig. 2b).
Immunofluorescence analysis using the CD31 endothe-
lial cell marker at day 7 in culture revealed the highest
CD31 expression for iPSC-ECs seeded on PG73 scaffolds
at high flow rate (3.49 ± 0.11%, p < 0.01; Fig. 2c), followed
by PG55 scaffolds at high flow rate (2.68 ± 0.41%, p <
0.05; Fig. 2c), when compared to PCL.
Cross-sectional staining of seeded scaffolds using DAPI
nuclei counterstain revealed no differences in infiltration of
iPSC-ECs into the scaffolds, irrespective of fiber size or com-
position at day 7 in culture (Additional file 2: Figure S2).
The elevated growth rates and high CD31 expression
suggested an advantage for using PG73 high flow rate
scaffolds as candidate engraftment platforms for subse-
quent in-vivo studies.
Preimplantation characterization of iPSC-EC-seeded PG73
scaffolds
To assess functional changes of iPSC-ECs seeded on
PG73 scaffolds after 7 days in culture, we analyzed
hypoxia-induced gene expression and scaffold remodeling
effects. When grown on tissue culture plastic under hyp-
oxic conditions, iPSC-ECs upregulated the expression of
epidermal growth factor (EGF) and placental growth fac-
tor (PlGF), while vascular endothelial growth factor
(VEGF) upregulation was highly variable. However, when
cultured on PG73 scaffolds under similar hypoxic condi-
tions, this upregulation was further enhanced by 1.8-fold,
3.17-fold, and 1.17-fold, respectively (4.86 ± 0.85 vs 2.67 ±
0.89-fold, 6.24 ± 2.01 vs 1.97 ± 0.86-fold, and 20.25 ± 4.28
vs 17.24 ± 10.87-fold, respectively, p < 0.05, p < 0.01;
Fig. 3a). The hypoxia-responsive function of iPSC-ECs on
PG73 scaffolds was enhanced compared to normal tissue
culture conditions.
To assess dedifferentiation of iPSC-ECs back to dermal
fibroblast phenotypes, iPSC-EC cultures on PG73 and
PCL scaffolds were assessed for fibroblast phenotypes
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compared to human dermal fibroblasts (Additional file 4:
Figure S4). Endothelial and fibroblast phenotypes were
assessed using the CD31 and Vimentin markers, respect-
ively. iPSC-ECs cultured on PCL scaffolds showed a 4.1-
fold decrease in CD31 expression (Additional file 4:
Figure S4B) and a 2.3-fold increase in fibroblast pheno-
type (Additional file 4: Figure S4C). These results suggest
that iPSC-ECs maintain their endothelial phenotypes
when cultured on PG73 scaffolds and dedifferentiate back
to fibroblast phenotypes on PCL scaffolds.
In-vivo engraftment of transplanted iPSC-ECs and iPSC-EC
PG73 scaffolds
Using our bioluminescence standard curve, we quanti-
fied 7-day iPSC-EC cell numbers on PG73 scaffolds at
concentrations of ~ 3 × 105 cells/scaffold. For subse-
quent in-vivo experiments, we used matched cell
concentrations for iPSC-EC alone injections. Biolumin-
escence was also used to quantify subsequent engraft-
ment and survival of iPSC-ECs in vivo. Within 1 h
following implantation, iPSC-ECs alone observed an
11.42-fold decrease in survival compared to iPSC-ECs
cultured on PG73 scaffolds (6.69 ± 3.73 vs 76.41 ± 19.56
radiance ratio, p < 0.001; Fig. 3b). Area under the curve
analysis revealed a 5.25-fold increase in total engraft-
ment of iPSC-ECs seeded on PG73 scaffolds compared
to injection alone (210.3 ± 67.22 vs 40.4 ± 16.16 radiance
ratio, p < 0.05; Fig. 3c). The magnitude and length of
engraftment of iPSC-ECs on PG73 scaffolds was
significantly increased compared to injection alone.
Fig. 2 a Bioluminescence standard curve of iPSC EC cell number, representative cell bioluminescence images (inset). b iPSC EC growth at 3 and 7
days on electrospun scaffolds of varying flow rate and PCL/gelatin blends. ***p < 0.001, **p < 0.01 compared to PCL (8 ml/h) control scaffolds
within the same time point. n = 5 scaffolds/group. c CD31 quantification of iPSC EC cultures on scaffolds at 7 days in vitro. *p < 0.05, **p < 0.01. n = 5
scaffolds/group. d Representative photographs of iPSC EC cultures stained with CD31 (red) and counterstained with DAPI (blue) at 5×; magnified im
ages at 10× (inset). Scale bar represents 100 μm, inset scale bar represents 10 μm. iPSC EC induced pluripotent stem cell derived endothelial cell, PCL
polycaprolactone, PG73 PCL/gelatin (70:30 ratio), PG55 PCL/gelatin (50:50 ratio), DAPI 4',6 diamidino 2 phenylindole
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Fig. 3 a Angiogenic cytokine gene expression of iPSC ECs cultured on tissue culture plastic (TCP) and PG73 (16 ml/h scaffolds) in normoxia vs hypoxia.
Values presented as fold change normalized to normoxia. *p < 0.05, **p < 0.01. n = 5 samples/group. b In vivo engraftment curves measured through
IVIS bioluminescence measurement of iPSC ECs and iPSC EC seeded PG73 scaffolds over 5 days. ***p < 0.001, *p < 0.05. n = 5 samples (animals)/group.
c Area under the curve quantification of engraftment bioluminescence curves. *p < 0.05. n = 5 samples (animals)/group. d Representative bioluminescence
photographs of animals implanted with experimental groups over 5 days. EGF epidermal growth factor, PlGF placental growth factor, VEGF vascular
endothelial growth factor, PG73 polycaprolactone/gelatin (70:30 ratio), iPSC EC induced pluripotent stem cell derived endothelial cell, AUC area under
the curve
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Bioluminescence was no longer observed in either
group after day 5.
Blood perfusion
Serial Doppler measurements of the implantation sites
were taken to non-invasively assess blood reperfusion
following tissue injury. Repeated measures analysis of
the perfusion curves over 9 days revealed a significant
increase in blood perfusion in the tissue surrounding
iPSC-EC-seeded PG73 scaffolds compared to control
wounds (Fig. 4a). The largest difference in perfusion was
observed on day 7 where iPSC-EC-seeded PG73
scaffolds exhibited a 2.04-fold increase compared to con-
trol wounds (6.53 ± 0.69 vs 3.20 ± 0.49 × 102 flux units,
p < 0.0001; Fig. 4a). The implantation of PG73 scaffolds
alone appeared to also increase wound perfusion,
although this was not significant from control wounds.
Wound explants macroscopically appeared to show in-
creased vasculature surrounding both iPSC-EC-seeded
and acellular PG73 scaffolds. Increased vascularity was
observed contacting iPSC-EC-seeded scaffolds, whereas
in PG73 scaffolds the vasculature was localized to the
scaffold periphery (Fig. 4b).
Functional angiogenesis
To determine the extent of functional angiogenesis at
the implantation site, immunohistochemical analysis was
conducted by double staining of SM-α actin (smooth
muscle cell) and CD31 (endothelial cell) markers. Quan-
tification of total arteriole density, identified as vessels
positive for CD31 and SM-α actin (CD31+/SM-α actin+),
revealed a 4.65-fold increase in iPSC-EC-seeded PG73
scaffolds compared to control, iPSC-EC alone, and PG73
alone at day 2 (0.12 ± 0.01 vs 0.03 ± 0.01, 0.03 ± 0.01,
and 0.07 ± 0.01 arterioles/mm2, respectively, p < 0.05, p
< 0.001; Fig. 5a). Arteriole localization analysis showed
that this increased arteriole density was localized to the
tissue surrounding iPSC-EC-seeded PG73 scaffolds
(Fig. 5b). Arteriole analysis at day 9 showed no observ-
able differences amongst all groups. Furthermore, the
diameter of arterioles present in both scaffold groups,
iPSC-EC-seeded PG73 scaffolds and PG73 scaffolds,
were significantly increased compared to control wounds
(61.86 ± 4.05 and 56.27 ± 3.49 vs 21.24 ± 2.29 μm, re-
spectively, p < 0.0001; Fig. 5c). At day 9, this trend
remained; however, arteriole diameters in iPSC-EC-
seeded PG73 scaffold groups were even greater than in
Fig. 4 a Laser Doppler blood perfusion curves of areas encompassing wound site, representative photographs and Doppler images (inset). *p <
0.05, **p < 0.01, ***p < 0.001. n = 5 samples (animals)/group. b Representative macroscopic photographs of wound explants at day 2 and day 9,
scale bar represents 3 mm. PG73 polycaprolactone/gelatin (70:30 ratio), iPSC EC induced pluripotent stem cell derived endothelial cell
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PG7 scaffolds when both were compared to control
wounds (63.76 ± 3.68 and 47.86 ± 11.25 vs 22.1 ± 2.7
μm, p < 0.01, p < 0.05; Fig. 5c).
Local innate immune response
Local innate immune response following implantation was
assessed through immunohistochemical analysis of neu-
trophils and macrophages using the neutrophil-elastase
and CD68 markers, respectively. Scaffold implantation
(both iPSC-EC-seeded and scaffolds alone) induced a 3.5-
fold increase in neutrophil response compared to control
wounds 2 days following implantation (~ 0.07 ± 0.01 vs
0.02 ± 0.01 stained area, p < 0.001; Fig. 6a). Additionally,
iPSC-EC seeding did not further enhance neutrophil re-
sponses to PG73 scaffolds (0.07 ± 0.01 vs 0.07 ± 0.02
stained area; Fig. 6b). By day 9, neutrophil levels were
equally resolved amongst all groups. Macrophage analysis
revealed a 2-fold increase in PG73 scaffolds alone com-
pared to control wounds (1.05 ± 0.05 vs 0.54 ± 0.01 × 10
−2 stained area, p < 0.0001; Fig. 6c). iPSC-EC seeding fur-
ther enhanced this macrophage response (2.04 ± 0.03 vs
0.54 ± 0.01 × 10−2 stained area, p < 0.0001; Fig. 6c). Ana-
lysis of macrophage localization showed an increased
presence of macrophages within iPSC-EC-seeded PG73
Fig. 5 a Functional angiogenesis quantification of arteriole density (vessels double stained for CD31+ and SMC α actin+). *p < 0.05, ***p < 0.001. n = 5
samples/group. b Quantification of arteriole location in surrounding tissue vs inside scaffold. **p < 0.01. n = 5 samples/group. c Quantification of average
arteriole diameter. ***p < 0.001, **p < 0.01, *p < 0.05. n = 5 samples/group. d Representative photographs of DAPI/CD31/SMC α actin merge, CD31, and
SMC α actin, respectively, at the wound site or tissue implant interface (dotted lines: above represents tissue, below represents scaffold) at day 2, scale bar
represents 100 μm. SMC α smooth muscle cell actin, CD31 cluster of differentiation 31 (endothelial marker), PG73 polycaprolactone/gelatin (70:30 ratio),
iPSC EC induced pluripotent stem cell derived endothelial cell, DAPI 4',6 diamidino 2 phenylindole
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scaffolds compared to PG73 scaffolds alone (1.5 ± 0.2 vs
0.8 ± 0.2, p < 0.01; Fig. 6d). At day 9, macrophage num-
bers in PG73 scaffolds were increasing, while in iPSC-EC-
seeded scaffolds they appeared to be resolving (Fig. 6d).
Angiogenic cytokine modulation and localization
Angiogenic cytokine analysis at the implantation site
was determined using immunohistochemical analysis of
the classic proangiogenic cytokines placental growth fac-
tor (PlGF) and vascular endothelial growth factor
(VEGF). At day 2, significant upregulation of total PlGF
was observed in iPSC-EC-seeded PG73 scaffolds com-
pared to control, iPSC-EC alone, and PG73 alone (0.11
± 0.01 vs 0.06 ± 0.01, 0.05 ± 0.01, and 0.03 ± 0.01
stained area, respectively, p < 0.05; Fig. 7a). Localization
analysis showed that PG73 scaffold implantation alone
decreased the baseline levels of PlGF found in control
wounds (0.01 ± 0.01 vs 0.06 ± 0.01 stained area, p <
0.05; Fig. 7b) At day 9, no differences in PlGF total or
localization were observed.
Analysis of VEGF expression at day 2 showed a signifi-
cant upregulation of VEGF in iPSC-EC-seeded PG73
scaffolds compared to control, iPSC-EC alone, and PG73
alone (0.14 ± 0.01 vs 0.07 ± 0.01, 0.04 ± 0.01, and 0.08 ±
0.01 stained area, respectively, p < 0.05, p < 0.01, p <
0.001; Fig. 8a). Localization analysis revealed that PG73
scaffolds alone resulted in a decrease of VEGF in the sur-
rounding tissue compared to iPSC-EC-seeded PG73
scaffolds and control wounds (0.03 ± 0.01 vs 0.07 ± 0.01
and 0.06 ± 0.01 stained area, p < 0.05; Fig. 8b). At day 9,
total VEGF expression was significantly increased in PG73
scaffolds alone and iPSC-EC-seeded PG73 scaffolds com-
pared to control wounds (0.17 ± 0.03 and 0.24 ± 0.01 vs
0.03 ± 0.01 stained area, respectively, p < 0.001, p <
0.0001; Fig. 8a). Between the groups, the highest expres-
sion of VEGF was observed in PG73 scaffolds alone. Fur-
thermore, this increased VEGF expression was localized
to within PG73 scaffolds (0.19 ± 0.01 vs 0.11 ± 0.03
stained area, p < 0.05; Fig. 8b).
Discussion
Induced pluripotent stem cell-derived endothelial cells
(iPSC-ECs) have been identified as a promising cell
population with potential for increasing therapeutic
angiogenesis. Derived from iPSCs possessing unlim-
ited sources and renewal capacity, iPSC-ECs have
demonstrated regenerative properties consistent with
their stem cell origins. Typically generated from
patient-specific cell harvests, iPSC-derived cell therap-
ies mitigate major cell therapy concerns regarding
immunogenicity and subsequent cell rejection. Add-
itionally, the advent of iPSC banking has paved the
way for the delivery of nonautologous iPSCs without
evoking immune rejection [21], thereby reducing the
potential time, cost, and invasiveness of iPSC-EC
therapy. However, extending the collective
Fig. 6 a Quantification of total neutrophil levels at wound site. **p < 0.01. n = 5 samples/group. b Quantification of neutrophil location in
surrounding tissue vs within scaffold. c Quantification of total macrophage levels at wound site. **p < 0.01, ****p < 0.0001. n = 5 samples/group.
d Quantification of macrophage location in the surrounding tissue vs within the scaffold. p < 0.05 comparing macrophages within scaffolds only.
n = 5 samples/group. Tissue implant interface marked by dotted lines: above represents tissue, below represents scaffold. NE neutrophil elastase,
iPSC EC induced pluripotent stem cell derived endothelial cell, PG73 polycaprolactone/gelatin (70:30 ratio), DAPI 4',6 diamidino 2 phenylindole
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translational benefits of iPSC-ECs for therapeutic
angiogenesis requires engraftment strategies that can ex-
tend their lifetime and maintain their function in vivo.
Using a simple PCL/gelatin composite scaffold system,
we assessed the influence of fiber width and gelatin
content on iPSC-EC growth and function due to the
well-characterized history of these synthetic and natural
materials [22, 23]. The stable transfection of luciferase
into our iPSC-ECs facilitated both accurate quantifica-
tion of cell numbers and the capacity for non-invasive
imaging in vivo. Using a matrix of conditions including
increasing gelatin content and fiber width, we deter-
mined that gelatin-containing scaffolds electrospun at
high flow rates supported the highest rates of iPSC-EC
growth. This is consistent with previous reports of the
upregulation of gelatin-binding integrins, such as α5β1,
on the surface of ECs differentiated from iPSCs [24].
When combined with increased fiber widths, gelatin-
based microfiber scaffolds provided greater cell surface
area for integrin-mediated signaling, a key facilitator of
growth and proliferation [22]. However, of the two
gelatin blends, PG73 promoted higher expression of
CD31, suggesting a greater conservation of iPSC-EC
endothelial cell phenotype. This effect may have been
driven by the inherent structural features of nanofibrous
topographies that enable the formation of cellular archi-
tectures thought to recapitulate native morphology and
phenotype [25]. However, with high concentrations of
gelatin the structural integrity of fibers become increas-
ingly compromised due to heightened water solubility
and mechanical weakening [23]. Despite the availability
of crosslinking methods to resolve this issue, these
Fig. 7 a Quantification of total PlGF expression at the wound site. *p < 0.05. n = 5 samples/group. b Quantification of PlGF expression location in
surrounding tissue vs within the scaffold. *p < 0.05 comparing PlGF expression within the surrounding tissue only. n = 5 samples/group. c
Representative photographs of PlGF staining with DAPI counterstain, scale bar represents 100 μm. Tissue implant interface marked by dotted
lines: above represents tissue, below represents scaffold. PlGF placental growth factor, iPSC EC induced pluripotent stem cell derived endothelial
cell, PG73 polycaprolactone/gelatin (70:30 ratio), DAPI 4',6 diamidino 2 phenylindole
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approaches rely on cytotoxic reagents which impair scaf-
fold function for cell delivery applications [26]. Alterna-
tively, blends with synthetic polymers possessing high
mechanical strength and hydrophobicity such as PCL
are employed to overcome these structural shortcom-
ings. However, while pure PCL scaffolds may possess
greater mechanical stability, they lack the appropriate
cell binding domains for optimal cellular interaction.
Ideal blends consisting of appropriate amounts of PCL
and gelatin, such as those observed in PG73 blends, are
often required to effectively balance cell adhesion/prolif-
eration and structural integrity, respectively. While the
levels of gelatin content in PG73 scaffolds are capable of
supporting iPSC-EC growth, they do not appear to nega-
tively impact the structural integrity or degradation
characteristics of the scaffold.
Characterization of iPSC-EC-seeded PG73 scaffolds
prior to implantation showed that scaffolds preserved
the iPSC-EC phenotype and function after 7 days in cul-
ture. The possibility of dedifferentiation to original der-
mal fibroblast phenotypes appears limited given the lack
of fibroblast marker expression [27, 28]. Combined with
high CD31 expression, this suggests that the iPSC-EC
endothelial cell phenotype is best preserved on PG73
scaffolds. Furthermore, hypoxia-induced gene expression
was enhanced on PG73 scaffolds when compared to
conventional 2D tissue culture surfaces. This functional
response is likely more representative of their in-vivo ac-
tions because they assume more native-like in-vivo
morphologies on 3D surfaces compared to 2D. This en-
hanced functional response is highly promising for aug-
menting in-vivo angiogenesis as the upregulation of
Fig. 8 a Quantification of total VEGF expression at the wound site. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. n = 5 samples/group.
b Quantification of VEGF expression location in surrounding tissue vs within the scaffold. *p < 0.05 comparing VEGF expression within the
surrounding tissue only, #p < 0.05 comparing VEGF expression within scaffolds only. n = 5 samples/group. c Representative photographs of
VEGF staining with DAPI counterstain, scale bar represents 100 μm. Tissue implant interface marked by dotted lines: above represents tissue, below
represents scaffold. VEGF vascular endothelial growth factor, iPSC EC induced pluripotent stem cell derived endothelial cell, PG73 polycaprolactone/
gelatin (70:30 ratio), DAPI 4',6 diamidino 2 phenylindole
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EGF, PlGF, and VEGF is classically associated with
underlying host angiogenic mechanisms [29–31]. Taken
together, the provision of simple scaffold structural and
signaling cues greatly enhanced the growth of iPSC-ECs,
while preserving their phenotype and promoting the ex-
pression of key proangiogenic factors. This suggests that
the development of more nuanced and complex scaffold
designs could provide further functional enhancements
and cell survival in future studies.
We next examined the functional effects of PG73 scaf-
folds on iPSC-ECs in vivo, tracking cell survival and re-
tention using non-invasive imaging of the luciferase cell
reporter. The administration of iPSC-ECs alone resulted
in poor survival consistent with the weight of clinical
findings for traditional stem cell therapy [8]. Most cells
were lost within 1 h of injection. These results are more
closely representative of native engraftment conditions,
compared to previous investigations of iPSC-EC function
which require the use of severe combined immunodefi-
cient (SCID) mice to enhance cell engraftment [15, 16].
The use of PG73 scaffolds extended the in-vivo lifetime
of transplanted iPSC-ECs by improving structural
support and providing signaling cues in the wounded
area. Nanofibrous scaffolds offer a 3D platform that
provides some mimicry of the in-vivo structural environ-
ment, increasing the likelihood of iPSC-EC engraftment.
While gelatin-based nanofibrous scaffolds extend the
in-vivo lifetime of transplanted iPSC-ECs up to 3 days,
future biomaterial strategies addressing additional fac-
tors impairing cell engraftment, including host inflam-
matory responses [32] and inadequate nutrient/growth
factor cues [33], may help to encourage iPSC-EC in-vivo
growth and further enhance engraftment. For example,
enhancements in scaffold porosity [34] or the provision
of growth factors [35] may prove beneficial.
Indeed, we have determined previously that human
iPSC-ECs are sensitive to the diameter and alignment of
nanofibrillar collagen scaffolds [16]. Aligned nanofibrillar
collagen fibrils (30 nM in diameter) guide cellular
organization, modulate endothelial inflammatory re-
sponse, and enhance cell survival after implantation in
normal and ischemic tissues. Human iPSC-ECs cultured
on aligned scaffolds persisted for over 28 days, as
assessed by bioluminescence imaging, when implanted
into the ischemic murine hindlimb of NOD-SCID mice
[16, 17]. By contrast, ECs implanted on scaffolds without
nanopatterning generated no detectable bioluminescent
signal by day 4 in either normal or ischemic tissues [36].
To assess the functional effects of increased cell
survival, we first used laser Doppler imaging to non-
invasively quantify in-vivo blood perfusion. Perfusion for
PG73 scaffolds alone, while not significantly improved
compared to controls, showed some improvements, an
effect previously demonstrated by other acellular
biomaterial platforms [37, 38]. These previous studies
suggest that altered tissue remodeling arising from the
introduction of foreign materials coupled with the highly
invasive nature of native endothelial cells following is-
chemic injury influence proangiogenic conditions. Our
findings demonstrate that further scaffold supplementa-
tion with iPSC-ECs significantly augments scaffold-
mediated perfusion. Macroscopically, the enhanced Dop-
pler signal appeared to correlate well with the observa-
tion of increased vasculature around the scaffolds at
explant, particularly for the iPSC-EC-seeded PG73 scaf-
folds. To confirm this observation, we used immunohis-
tochemistry to examine the density of arteriole vessels as
a marker for functional angiogenesis.
Arterioles are more stable blood-carrying vessels com-
pared to capillaries [39] and their diameter is directly
connected to the volume of blood flow through the
vessel [40]. PG73 scaffolds alone induced the forma-
tion of some large-diameter arterioles, explaining the
modest increases in perfusion observed through Dop-
pler imaging. The further increase in the density of
these large-diameter arterioles at early time points
correlated well with the greater perfusion levels of
iPSC-EC-seeded PG73 scaffolds. The functional en-
hancement of angiogenesis in the presence of iPSC-
ECs is consistent with previous reports showing acute
benefits in a hindlimb ischemia model and in vitro
[11]. To gain further insights into the mechanisms
underpinning this effect, we quantified some of the
key angiogenic regulators.
iPSC-EC scaffold-mediated augmentation of host angio-
genesis is a complex process regulated by innate immune
cells and proangiogenic cytokines. Observed increases in
arteriole diameter following implantation surgery arise
from vasodilation of nearby blood vessels allowing in-
creased permeability of innate immune cells responding
to the material implant [41]. This characteristic foreign
body response is hallmarked by the increased presence of
neutrophils and macrophages around the implant [42].
While an elevated host-inflammatory response to exogen-
ous cell delivery is common, it does not appear to be the
driving force behind increased angiogenic activity sur-
rounding iPSC-EC-seeded scaffolds in this study. Equal
levels of neutrophils were observed in both iPSC-EC-
seeded scaffolds and control PG73 scaffolds alone [43].
Additionally, macrophage infiltration, typically observed
in the later stages of the foreign body response, appeared
to resolve more quickly for iPSC-EC-seeded scaffolds
compared to scaffolds alone. Instead, the unexpected early
increase in macrophages surrounding iPSC-EC-seeded
scaffolds following implantation suggests altered tissue
remodeling events. Macrophages have the capacity to in-
fluence multiple phases of the angiogenic process, includ-
ing alterations of the local extracellular matrix and
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induction of endothelial cell migration and proliferation
through angiogenic cytokine release [44].
Increased iPSC-EC engraftment in the first days post
implantation coincides with heightened PlGF expression,
a potent macrophage chemoattractant [45]. This en-
hanced macrophage presence at the implantation site,
along with elevated expression of the classical angiogenic
cytokine VEGF, may account for the increased density of
large-diameter arterioles. Localization analysis of these
cytokines revealed that these angiogenic factors originate
from within the scaffold, possibly from engrafted iPSC-
ECs and macrophages responding to the implant.
Equally important to the therapeutic translation of these
processes is the timing of cytokine release. Although
enhanced VEGF expression in scaffolds alone is eventu-
ally achieved at similar expression levels to iPSC-EC-
seeded scaffolds by day 9, levels at day 2 are significantly
improved only in the presence of iPSC-ECs. The benefits
of iPSC-EC-mediated increases in angiogenesis arise
from this timely augmentation of blood perfusion imme-
diately following implantation, in addition to the longev-
ity of these effects even after iPSC-EC engraftment is no
longer observed. Further research into identifying add-
itional factors underlying this function is necessary for
optimizing the angiogenic potential of future iPSC-EC
scaffold therapies.
Conclusion
The integration of biomaterials with iPSC-ECs is a
highly promising and innovative approach for thera-
peutic angiogenesis. Optimization of these approaches
for future therapy requires a comprehensive understand-
ing of cell–material interactions and the resulting effects
following implantation of these combined constructs.
The findings of this study identify important scaffold
design parameters which influence iPSC-EC behavior
and function. These initial observations serve as prelim-
inary criteria for developing candidate biomaterial plat-
forms with enhanced capacity to support iPSC-EC
engraftment and viability in vivo. Further understanding
of the mechanisms underlying the combined effects of
iPSC-ECs and their engraftment platforms will more
readily lead to the development of enhanced iPSC-EC
scaffold designs with clinical applications for therapeutic
angiogenesis. The findings of this work help highlight
this emerging cell–biomaterial field of regenerative
medicine with significant implications for the treatment
of ischemic injury.
Additional files
Additional file 1: Figure S1. showing (A) representative SEM
photographs of PG73 and PG55 scaffolds before and after soaking in PBS for 7
days, scale bar represents 10 μm. (B) Scaffold cross section images for porosity
analysis. n 5 samples/group, scale bar represents 100 μm. (TIFF 19523 kb)
Additional file 2: Figure S2. showing (A) analysis of iPSC EC infiltration
into scaffolds, representative photographs of scaffold cross sections
stained with DAPI. n 100 cells/scaffold, scale bar represents 100 μm. (B)
Young’s modulus and (C) ultimate tensile strength (UTS) of PG73 scaffolds
before and after wetting. n 5 samples/group. (D) Degradation rate of
PG73 scaffolds compared to PCL over 4 days in an accelerated Protease
XIV degradation solution. n 3 samples/group. (TIFF 12785 kb)
Additional file 3: Figure S3. showing (A) bioluminescence standard
curve with upper limit of iPSC EC concentration detection before IVIS camera
saturation, inset. (B) Lower limit of iPSC EC concentration detection after
background/noise subtraction. n 5 samples/group. (TIFF 44988 kb)
Additional file 4: Figure S4. showing (A) dedifferentiation of iPSC ECs
seeded on PG73 vs PCL scaffolds after 7 days culture in vitro. Photographs using
(B) immunostains for CD31+ for endothelial phenotype and (C) vimentin+ for
fibroblast phenotype. *p < 0.05. n 3 samples/group, scale bar represents 40
μm. (TIFF 51787 kb)
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Chapter 5 
Bioactive Materials Facilitating Targeted and 
Local Modulation of Inflammation 
  


immune response to facilitate prolonged functional
beneﬁts.
We have identiﬁed macrophages and their broad
spectrum of phenotypes as master effectors of the
foreign body response toward implanted materials. At
the 2 ends of the spectrum are the M1 (pro-inﬂam-
matory) and M2 (anti-inﬂammatory) phenotypes,
which regulate a host of inﬂammatory cytokines to
either propagate or halt innate inﬂammation, respec-
tively. Modiﬁcation of the material surface to induce
the M2 phenotype of responding macrophages may
potentially represent an effective means of mitigating
foreign body responses to implanted materials.
In the present study, we developed a novel off-the-
shelf bioactive device coating for local and lasting
modulation of the inﬂammatory response to implants.
A plasma immersion ion implantation (PIII) surface
treatment was used that facilitates the rapid covalent
attachment of biomolecules while preserving their
bioactivity (6). One of the most well-established and
highly documented biomolecules responsible for M2
macrophage phenotype polarization is the cytokine
IL-4 (7). Bioactive signaling chemokines such as IL-4
have not previously been immobilized on material
surfaces without chemical linkers, representing a
fundamentally new off-the-shelf approach to local
regulation of inﬂammation. Herein we examined the
in vitro behavior of macrophages in response to
bioactive IL-4 surfaces before assessing the in vivo
inﬂammatory responses in 2 distinct mouse models.
Comprehensive immunohistochemical analysis of
both subcutaneous and carotid arterial graft implants
was used to quantitatively assess macrophage
phenotype, local cytokine expression, and measures
of functional outcome (including ﬁbrous encapsula-
tion and neointimal hyperplasia).
METHODS
PIII SURFACE TREATMENT. Surface modiﬁcation of
electrospun polycaprolactone (PCL) scaffolds was
conducted by using PIII as previously described (8).
Brieﬂy, nitrogen was admitted into a custom-built
vacuum chamber to a working pressure of 2  10–3
Torr, and plasma discharges were generated by
inductively coupled radiofrequency power at a fre-
quency of 13.56 MHz. Scaffolds were placed on an
electrically biased stainless-steel holder. Ion acceler-
ation was achieved through application of –20 kV
pulses with a temporal width of 20 ms at a frequency
of 50 Hz, drawing a current of 1.3 mA. PIII treatment
was run for 800 s, providing ion ﬂuences of 1  1016
ions/cm2. Characterization methods of PIII-treated
surfaces can be found in the Supplemental Methods.
BIOACTIVE IL-4 SURFACE CREATION. For in vitro
experiments, scaffolds were biopsy punched into 5-
mm diameter circular discs and placed into Eppen-
dorf tubes. Recombinant mouse IL-4 (2 mg/ml in
sterile phosphate-buffered saline) was added to each
scaffold for 1 h at room temperature. To test IL-4
attachment, scaffolds were washed in sodium
dodecyl sulfate (5% in phosphate-buffered saline) for
4 h at room temperature before enzyme-linked
immunoadsorbent assay (ELISA) using an anti–IL-4
monoclonal antibody (Thermo Fisher Scientiﬁc, Wal-
tham, Massachusetts) and horseradish peroxidase–
conjugated secondary antibody (Abcam, Cambridge,
Massachusetts). For in vivo experiments, both ﬂat
scaffolds and PCL conduits (0.5 mm diameter) were
incubated in recombinant mouse IL-4 (2 mg/ml in
sterile phosphate-buffered saline) for 1 h at room
temperature and rinsed in sterile phosphate-buffered
saline before implantation.
In v ivo performance of b ioact ive IL-4
subcutaneous implants . Study approval was ob-
tained from the Sydney Local Heath District Animal
Welfare Committee (protocol number 2013/050). Ex-
periments were conducted in accordance with the
Australian Code of Practice for the Care and Use of
Animals for Scientiﬁc Purpose. Mice were given four
1.5-cm incisions (two rows side-by-side) on their
dorsal surfaces to create subcutaneous pockets, as
previously described (9). Scaffolds were then inserted
into each pocket (5 mice per time point equaling 5
scaffolds per group per time point) and sutured
closed by using 6-0 silk sutures. Explants were taken
at 3, 7, and 14 days’ post-implantation; analysis is
detailed in the Supplemental Methods.
In v ivo performance of b ioact ive IL-4 vascular
grafts . Study approval was obtained from the Syd-
ney Local Heath District Animal Welfare Committee
(protocol number 2015/016). Experiments were con-
ducted in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientiﬁc
Purpose. C57/BL6 mice (male, 9 to 10 weeks old,
25  2 g) were purchased from Australian Bio-
Resources (Moss Vale, NSW, Australia). Vascular
grafts (5 per group) were implanted into the carotid
artery by using a previously described technique (10).
Brieﬂy, the right common carotid artery was double
ligated, and polyimide cuffs (Cole-Parmer North
America, Vernon Hills, Illinois) were placed around
each end. Overhanging arteries were everted on the
plastic cuff, and grafts were then sleeved over each
end and secured with 8-0 sutures. Clamps were
removed, and blood ﬂow was conﬁrmed with pulsa-
tion. After 28 days, mice were perfused with hepa-
rinized saline (50 U/ml), and the grafted carotid artery
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was isolated and dissected proximal and distal to the
graft. Analysis of the vascular cross-sections is
detailed in the Supplemental Methods.
RESULTS
CREATION OF A NOVEL IL-4–IMMOBILIZED
BIOMATERIAL SURFACE. Control surfaces were PIII
treated in nitrogen plasma for a duration of 800 s.
Energetic ions accelerated by the 20-kV negative bias
penetrate through the scaffold surface, breaking
chemical bonds along their path and displacing atoms
in the polymer structure. This results in a highly
crosslinked, dense, carbonized structure at the sur-
face of the scaffold (Figure 1A). The high density of
broken bonds and displaced atoms allow for creation
of new bonds (Figure 1B). The unpaired electrons that
remain manifest as reactive radical groups (Figure 1C)
embedded in the treated layer that gradually diffuse
to the surface via thermally activated, local restruc-
turing (Supplemental Results). Radical diffusion
leads to surface oxidation, allowing direct covalent
immobilization of IL-4 upon contact with the scaffold
surface (6). Mechanical testing of scaffolds (n 6 each
group) exhibited no signiﬁcant differences in Young’s
modulus or strain after PIII treatment (Supplemental
Figure 1).
Bioactive IL-4 surfaces were created by incubating
the PIII-treated surfaces in an IL-4 solution (2 mg/ml)
for 1 h at room temperature (Figure 1D). Robust, co-
valent immobilization was shown by washing sur-
faces in sodium dodecyl sulfate (5%) for 4 h at room
temperature to remove any passively adsorbed mol-
ecules (11,12), followed by IL-4 quantiﬁcation using
ELISA (n 3 each group) (Figure 1E). Although the
PIII-treated scaffolds retained IL-4 (bioactive IL-4),
IL-4 was completely removed from the untreated
PCL surfaces (passive IL-4).
BIOACTIVE IL-4 SURFACES MODULATE MACROPHAGE
PHENOTYPE IN VITRO. RAW264.7 murine macro-
phages were seeded onto bioactive IL-4 surfaces to
evaluate macrophage polarization (Figure 2A), as
commonly reported (13–15). Macrophage morphology
and material interaction were ﬁrst characterized by
using scanning electron microscopy. At 8 h post-
seeding, cells cultured on bioactive IL-4 surfaces
appeared more spread, with a notably rougher cell
surface (Figure 2B). Cytoskeletal morphologies,
observed by using confocal microscopy, further
showed strikingly different morphology. Expression
of M2 phenotype genes, arginase-1, CD163, CD206,
and IL-10 revealed that passive IL-4 surfaces
enhanced the expression of only arginase-1 and IL-
10 but had no signiﬁcant effect on CD163 or
CD206. Similarly, PIII-only surfaces signiﬁcantly
increased arginase-1 expression but not the other
markers. Only bioactive IL-4 surfaces signiﬁcantly
increased all marker expression at 8 h post-seeding
compared with control (Figure 2C). These results
show that IL-4 covalently immobilized on PIII-
treated surfaces robustly polarizes macrophages to-
ward an M2 phenotype and demonstrates that this
immobilization approach is necessary for sustained
bioactivity.
BIOACTIVE IL-4 SUBCUTANEOUS IMPLANTS
REDUCE INFLAMMATORY CYTOKINES AND FIBROUS
ENCAPSULATION. A 14-day subcutaneous mouse
back model of acute inﬂammation was initially used
to evaluate the in vivo functionality of bioactive IL-4
surfaces (16) (5 scaffolds per group) (Figure 3A), before
further evaluation in a vascular context. Immuno-
staining markers for total macrophages (CD68þ), M1
(major histocompatibility complex Class II), and M2
(CD206) phenotypes were used to assess macrophage
responses (Figure 3B). Increasing macrophage
recruitment, observed on control surfaces, was
reduced by 79  6% and 86  7% on bioactive IL-4
surfaces at days 7 and 14, respectively (Figure 3B,
top). Bioactive IL-4 surfaces also increased M2
macrophage polarization by 159  11% at day 3, sug-
gesting earlier M2 polarization compared with control
(Figure 3B, middle). Bioactive IL-4 surfaces also
exhibited a 360  15% higher M2/M1 macrophage ratio
at day 14 compared with control, indicating a pre-
dominantly M2 phenotype residing at the implant
surface in the late phases post-implantation
(Figure 3B, bottom). These results were observed in
representative images illustrating a large accumula-
tion of macrophages on control surfaces with a pre-
dominantly M1 phenotype. In contrast, bioactive IL-4
surfaces exhibited a signiﬁcant reduction in total
macrophage accumulation and an enhancement of
the M2 phenotype (Figure 3C).
To corroborate these ﬁndings, quantitative poly-
merase chain reaction (qPCR) and ELISA analysis for
classic M1 and M2 markers were conducted at days 3
and 7 post-implantation to assess gene and protein
expression changes, respectively. qPCR results
revealed that bioactive implants had signiﬁcantly less
TNF-a and inducible nitric oxide synthase at day 3
(Supplemental Figure 2A) and the ELISA results
showed signiﬁcantly reduced IL-1b and IL-6 in bioac-
tive implants at days 3 and 7 (Supplemental Figure 2B).
These results were consistent with our immunohisto-
chemistry and validated the presence of a robust
anti-inﬂammatory microenvironment surrounding
bioactive subcutaneous implants by independently
demonstrating an upregulation of M2 markers and a
downregulation of M1 markers.
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FIGURE 1 Characterization of PIII Treatment on PCL Control Surfaces
(A) Plasma immersion ion implantation (PIII) schematic with representative images of control surfaces before (top) and after (bottom) treatment.
(B) Attenuated total reﬂectance Fourier transform infrared spectroscopy (ATR FT IR) surface characterization. (C) Electron paramagnetic resonance (EPR)
characterization. (D) Diagram of experimental groups. (E) Interleukin 4 (IL 4) retention enzyme linked immunoadsorbent assay (n 3 per group).
PCL polycaprolactone; RT room temperature; SDS sodium dodecyl sulfate.
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FIGURE 2 In Vitro Biofunctionality of IL-4 Bioactive Surfaces
(A) Schematic of experimental design. (B) Scanning electron microscopy (SEM) (top row; scale bar represents 50 mm) and confocal micro
scopy (bottom row; scale bar represents 5 mm) of cultured macrophages. (C) Quantitative polymerase chain reaction (qPCR) of M2 Phenotype
genes (n 5 per group). Abbreviations as in Figure 1.
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Further immunohistochemical analysis was conduct-
ed to conﬁrm the expression of inﬂammatory cyto-
kines (5 scaffolds per group). IL-10 and transforming
growth factor (TGF)-b were chosen as classic anti-
inﬂammatory cytokines, whereas IL-1b and TNF-a
are well-characterized pro-inﬂammatory cytokines
(17). Bioactive IL-4 surfaces increased IL-10
expression by 432  26% at day 7 compared with
controls (Figure 4A). TGF-b expression was also
increased 1025  11% at day 7 on bioactive IL-4
surfaces. Representative images show this increased
IL-10 and TGF-b present at the scaffold/tissue
interface in bioactive surfaces (Figure 4B). Corre-
sponding changes to classically pro-inﬂammatory
cytokines occurred at later time points, with
signiﬁcant differences at day 14. IL-1b and TNF-a
FIGURE 3 Implantation of Bioactive IL-4 Surfaces in Subcutaneous Mouse Model
(A) Experimental design schematic. (B) Immunohistological quantiﬁcation of macrophages at the implant surface: total CD68þ macrophages (top), CD206þ M2
polarization (middle), and M2/M1 (CD206þ/ major histocompatibility complex (MHC) Class IIþ) ratio (bottom). (C) Representative images of M2 (top row) and M1
(bottom row) macrophages. CD68 stained in green, CD206 stained in orange, and MHC Class II stained in purple. Dotted lines represent the interface between tissue
(above) and implant (below). Scale bar represents 60mm; n 5 per group. IHC immunohistochemical; other abbreviations as in Figure 1.
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FIGURE 4 Inﬂammatory Cytokine Quantiﬁcation at the Implant Surface In Vivo
(A) Immunohistological quantiﬁcation of anti inﬂammatory cytokines IL 10 (top) and transforming growth factor (TGF) b (bottom). (B) Representative images of IL 10
(top) and TGF b (bottom) expression at the implant surface stained in white and yellow respectively. (C) Immunohistological quantiﬁcation of pro inﬂammatory
cytokines IL 1b (top) and tumor necrosis factor (TNF) a (bottom). (D) Representative images of IL 1b (top) and TNF a (bottom) expression at the implant surface
stained in purple and orange respectively. Dotted lines represent the interface between tissue (above) and implant (below). Scale bar represents 40 mm; n 5 per
group. Abbreviations as in Figure 1.
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expression was 84  7% and 53  5% less, respec-
tively, on bioactive IL-4 surfaces compared
with control (Figure 4C). Again, representative
images clearly show these striking changes at
the material interface where bioactive IL-4 implants
seem to all drastically reduce IL-1b and TNF-a
(Figure 4D).
We next sought to characterize functional changes
arising from an increased proportion of M2 macro-
phages and positive regulation of local cytokine pro-
duction. The ﬁbrotic capsule thickness for the control
implants increased steadily over time, as expected,
from 90  5.1 mm at day 3 to 276.6  132.1 mm by day 14
(Figure 5A). In contrast, the capsule thickness on
bioactive IL-4 surfaces was reduced at all time points
with a ﬁnal reduction of 65  4% at day 14, compared
with control, evident in representative images
(Figure 5B). Furthermore, peak collagen deposition in
PCL controls occurred at day 7 comprising 3.8  2% of
the capsule area, with less (2.0  0.7%) by day 14
(Figure 5C). In bioactive IL-4 surfaces, collagen was
reduced at day 7 with a signiﬁcant reduction at day
14, as seen in representative images (Figure 5D). Re-
ductions in collagen deposition over time further
suggest signiﬁcant modulation of the host foreign
body response.
BIOACTIVE IL-4 SYNTHETIC ARTERIAL GRAFTS
REDUCE LOCAL INFLAMMATION AND NEOINTIMAL
HYPERPLASIA. Small diameter vascular grafts were
manufactured with bioactive IL-4 surfaces on both
the luminal and adventitial surfaces, implanted into
an established mouse carotid interposition grafting
model, and explanted at 28 days (Figure 6A). Consis-
tent with results from the subcutaneous implant
study, IL-4 grafts signiﬁcantly reduced total macro-
phages present by 54  6% compared with control
(Figure 6B). These macrophages also showed a 47 
12% increase in the M2 phenotype and a correspond-
ing decrease in the M1 phenotype by 52  9%,
demonstrating similar macrophage polarization ef-
fects. This outcome was further supported by a 93 
11% increase in the M2/M1 ratio of bioactive IL-4
grafts compared with control. These changes are
highlighted in representative images, showing fewer
total macrophages and enhanced expression of CD206
with less major histocompatibility complex class II
(Figure 6C).
Further examination revealed that anti-
inﬂammatory IL-10 and TGF-b levels were signiﬁ-
cantly increased by 122  11% and 539  35%,
respectively, in bioactive IL-4 grafts compared
with controls (Figures 7A and 7B). In addition,
FIGURE 5 Functional Outcomes of Bioactive IL-4 Surfaces In Vivo
(A) Measurement of ﬁbrotic capsule formation/thickness at the implant surface (top). (B) Representative hematoxylin and eosin (H&E) stains of ﬁbrotic capsules.
(C) Quantiﬁcation of collagen deposition at the implant surface. (D) Representative trichrome stains of collagen (green) within the ﬁbrotic capsule, highlighted by
arrows. Dotted lines represent the interface between tissue (above) and implant (below). Scale bar represents 50 mm, n 5 per group. IL 4 interleukin 4.
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pro-inﬂammatory IL-1b andTNF-a expressionwas 43
9% and 50  3% less in bioactive IL-4 grafts (Figures 7C
and 7D). Representative images of graft cross-sections
demonstrate clear increases in levels of IL-10 and
TGF-b, as well as corresponding reductions in IL-1b
and TNF-a (Figure 7E).
To conﬁrm these ﬁndings, qPCR and ELISA ana-
lyses were conducted on vascular grafts at days 3 and
7 post-implantation. qPCR results showed that the
bioactive grafts had signiﬁcantly less TNF-a and
inducible nitric oxide synthase at days 3 and 7, in
addition to reduced CD86 at day 7 (Supplemental
Figure 3A). ELISA results supported that bioactive
grafts had less IL-1b, IL-6, and TNF-a at day 7
(Supplemental Figure 3B). Consistent with the
immunohistochemistry data, these additional results
further support our proposed immunomodulatory
effects of bioactive surfaces.
In a vascular graft context, inﬂammatory processes
drive both ﬁbrous encapsulation and neointimal
FIGURE 6 Investigation of IL-4 Bioactive Surfaces for Synthetic Vascular Grafts
(A) Experimental design schematic; vascular graft dimensions 0.5 mm (inner diameter)  6 mm length. (B) Representative immunostained images of macrophage
responses; M2 (top row) and M1 (bottom row)macrophages. CD68 stained in green, CD206 stained in orange, and MHC Class II stained in purple. Scale bar represents
500 mm. (C) Quantiﬁcation ofCD68þ total macrophages (top), CD206þ M2 polarization (middle), MHC Class IIþ M1 polarization, and M2/M1 (CD206þ/MHC Class IIþ)
ratio (bottom). n 3 slides (each region of the graft) per animal, with a total of 5 animals per group. Abbreviations as in Figures 1 and 3.
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FIGURE 7 Immunohistochemical Analysis of Inﬂammatory Cytokines in Vascular Grafts
(A) IL 10. (B) TGF b. (C) IL 1b. (D) TNF a. (E) Representative images of cytokine expression within vascular graft cross sections: control (top row) versus bioactive
(bottom row). IL 10 stained in green, TGF b stained in white, IL 1b stained in orange, and TNF a stained in red. Scale bar represents 1 mm; n 3 slides (each region of
the graft) per animal, with a total of 5 animals per group. Abbreviations as in Figures 1 and 4.
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FIGURE 8 Functional Outcomes of Bioactive IL-4 Surfaces for Synthetic Vascular Grafts
(A) Quantiﬁcation of adventitia capsule thickness. (B) Quantiﬁcation of neointimal hyperplasia development along 3 segments of vascular graft lumen. (C) Repre
sentative images of capsule thickness on the adventitia of vascular grafts, scale bar represents 150 mm; representative magniﬁed images of vascular graft lumens
(inset). Scale bar represents 40 mm. Dotted lines represent the luminal edge of hyperplasia, and solid lines represent the luminal graft surface. n 3 slides (each region
of the graft) per animal with the average represented as the red dotted line; total of n 5 animal averages per group. IL 4 interleukin 4.
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hyperplasia leading to graft failure. Adventitial
capsule thickness on bioactive IL-4 grafts was 50  1%
less than control (Figure 8A). In addition, neointimal
hyperplasia in bioactive IL-4 grafts was signiﬁcantly
less throughout the length of the graft (Figure 8B). The
greatest decreases were observed at the proximal and
distal anastomoses, with a reduction of 69  6.7% and
61  6.1%, respectively, relative to control. The mid-
section of the graft also saw signiﬁcantly less hyper-
plasia (51  9.6%) compared with control (Figure 8C).
No signiﬁcant changes to re-endothelialization
were observed between the grafts (Supplemental
Figure 4). Further characterization of the neo-
intima observed increases in smooth muscle cells
and proliferating cells compared to control while
the elastin in the neointima was not signiﬁcantly
different (Supplemental Figure 5). Collectively,
these results suggest that local modulation of
macrophage phenotypes and cytokine proﬁles were
responsible for signiﬁcant reductions in neointimal
hyperplasia.
DISCUSSION
CAD has become increasingly characterized as a
chronic inﬂammatory disorder, prompting consider-
ation of new anti-inﬂammatory therapeutic in-
terventions. An overabundance of immune cells is
common to atherosclerosis progression and neo-
intimal hyperplasia development. The underlying
immune cell presence arises from a complex interplay
of inﬂammatory cytokines, which act to coordinate,
propagate, and sustain inﬂammatory responses.
Clinical evidence highlights the therapeutic potential
of inhibiting cytokine expression to reduce inﬂam-
mation and improve outcomes. Although the
deployment of cardiovascular materials and devices
in high-risk areas is an established treatment for CAD,
accelerated inﬂammatory responses are a major cause
of failure (18). In search of the next generation of CAD
therapies, there remains an unmet need for cardio-
vascular devices fabricated from materials capable of
modulating local inﬂammatory responses.
The present study describes rapid resolution of the
inﬂammatory response to implanted materials in 2
separate mouse models, leading to durable functional
improvements. Previous studies have shown the
feasibility of local modulation of inﬂammation, using
drug release or direct injection approaches to inﬂu-
ence cell populations and chemokine proﬁles (19).
Together, these studies have highlighted the limita-
tion of using nonspeciﬁc suppressive drugs and the
transient effects of these approaches, with most
studies showing changes only in the ﬁrst few days
after implantation. Our results show that electrospun
PCL scaffolds and conduits can be robustly function-
alized with bioactive IL-4 to drive rapid polarization
of macrophages to an anti-inﬂammatory M2
phenotype.
Multiple studies have now reported that implanted
materials that promote an early shift to more M2-like
macrophages at the material interface have an
improved host response. The “alternatively acti-
vated” M2 phenotype is driven by signaling from M2-
polarizing cytokines, including IL-4 (20). Previous
research on IL-4–mediated regulation of the local
response to materials has been limited to short-term
elution from ﬂat scaffolds. Examples include release
from silk scaffolds over 24 h successfully polarizing
macrophages in vitro (21) and microsphere-mediated
release from poly(lactic-co-glycolic acid) scaffolds
that increased the proportion of CD206þmacrophages
after 1 day in vivo, but local gene expression changes
beyond this time were inconsistent (20). Similarly,
release of IL-4 from polypropylene meshes showed
no change to the number of local macrophages but a
shift toward M2 phenotype at 14 days in a mouse
subcutaneous implant model (22). Together, these
studies illustrate the promise of early-stage macro-
phage polarization at the tissue implant interface to-
ward an M2 phenotype. However, the applicability of
this approach to any functional application, such as in
a high-blood ﬂow environment, has yet to be
performed.
Robust immobilization of IL-4 onto the surface of
PCL substrates was consistent with previous use of
PIII surface activation of polymers to immobilize
other biomolecules, including ﬁbrillin-1 to polytetra-
ﬂuoroethylene (PTFE) (23) and tropoelastin to
expanded polytetraﬂuoroethylene (ePTFE) (24) and
polyurethane conduits (6). In vitro macrophage in-
teractions with bioactive IL-4 surfaces provided evi-
dence of retained IL-4 bioactivity. The effects of IL-4
immobilization through PIII are consistent with the
transient and variable effects on gene expression
previously described for eluted IL-4 (20,21). PIII
treatment is also well suited to the modiﬁcation of
implanted materials due to the established beneﬁts of
a long shelf-life post-treatment and the rapid cova-
lent binding of a range of biomolecules during solu-
tion incubation (6). At the bedside, these off-the-shelf
features would allow for the preparation of bioactive
surfaces by simply taking pre-treated PIII materials/
devices off the shelf and immersing them in IL-4
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solutions, ready for transplant into patients with
minimal time and cost expenditures.
The ﬁndings of the present study suggest that
simultaneous changes to the local expression of both
pro- and anti-inﬂammatory cytokines may be a more
suitable approach to achieve rapid and comprehensive
resolution of inﬂammation. Modulating macrophage
phenotype and behavior is potentially an effective way
of accomplishing this goal, demonstrating a preferable
immunomodulatory strategy in the context of materials
for vascular repair. Furthermore, these changes led to
functional reductions in ﬁbrous encapsulation sustained
for at least 14 days. In contrast, studies using passive
release of IL-4 commonly report upregulation of M2
macrophages surrounding implants but typically no
signiﬁcant differences in total cell accumulation (20) or
macrophages (22) at the implant interface. In fact, M2
macrophage polarization is greatest at distances farthest
from the surface of drug elution, accentuating the
disadvantage of passive release strategies in which IL-4
diffuses away from the implant site. Signiﬁcant re-
ductions in cell accumulation and ﬁbrous encapsulation
seen on bioactive IL-4 surfaces demonstrate improved
functional outcomes compared with passive release
strategies. More broadly, our ﬁndings suggest the po-
tential utility for a diverse range of tissue repair appli-
cations. Previous studies have highlighted beneﬁts for
regulating the inﬂammatory response to scaffolds in the
context of soft tissue and wound repair, as well as
potentially in cardiac patches to treat myocardial
infarction in which the role of macrophage polarization
has recently been highlighted (25). Studies thus far share
the limitation of being restricted to analysis in tissue,
with none to date modulating inﬂammation in ﬂowing
blood.
The present study reports sustained effectiveness
in a vascular graft context with direct implications
for vascular materials and devices deployed in con-
tact with circulation. Regulating ﬁbrotic encapsula-
tion is important for limiting compliance mismatch
between the graft and adjacent native vasculature,
which has long been correlated with poor patency in
small-diameter applications (26). Restenosis, the
main source of long-term graft occlusion, is caused
by neointimal hyperplasia and widely accepted to be
inﬂammation driven. Previous studies have clearly
reported this link observing reduced neointima for-
mation after inhibition of leukocyte trafﬁcking (27),
release of dexamethasone (28), the cytotoxic drugs
paclitaxel and sirolimus (29), and speciﬁc anti-
inﬂammatory CX3CR1 antagonists (30). Although
these strategies have collectively shown promising
in vitro results, beneﬁcial long-term outcomes
in vivo have not been reported, with efﬁcacy often
limited to the period of drug elution. In addition to
the beneﬁt of immobilization to address these is-
sues, bioactive IL-4 surfaces drive a rapid shift of
the native immune response that would be expected
to have lasting effects long after the IL-4 bio-
molecules are removed from the surface. By
elevating M2 macrophage populations, yielding
favorable modulation of the inﬂammatory response
through regulation of both pro- and anti-
inﬂammatory cytokines, the foreign body response
is more quickly resolved. Our research has signiﬁ-
cant implications for improving the inﬂammatory
response to all implants, with potential applications
for cardiovascular devices in contact with ﬂowing
blood such as the prevention of foreign body
encapsulation and neointimal hyperplasia in small
diameter conduits.
STUDY LIMITATIONS. Limitations to this study
include the use of a small animal model of grafting,
with a nondiseased phenotype, and a short-time
frame of neointimal hyperplasia assessment. While
the mouse grafting model used in this study facili-
tates quantiﬁcation of clinically relevant endpoints
such as neointimal hyperplasia and re-endotheliali-
zation, the established pre-clinical pathway includes
larger animals including sheep. The sheep model
more closely resembles human pathology and in-
corporates additional considerations of graft efﬁcacy
including thrombogenicity and longer-term graft
performance. The wild-type mice used in this study
have a healthy vasculature, lacking the persistent
inﬂammatory environment commonly present in
atherosclerosis and CAD. Use of fat-fed or transgenic
animals may potentially beneﬁt future studies
investigating bioactive vascular grafts in cardiovas-
cular disease phenotypes. The ﬁndings of this study
justify the further assessment of bioactive IL-4 sur-
faces in the context of atherosclerosis and in larger
animal models with implications for improving the
efﬁcacy of all implants, including small diameter
vascular grafts.
CONCLUSIONS
The present study evaluated a novel bioactive device
coating that modulates macrophage phenotype and
extensively suppresses local inﬂammatory responses.
The bioactivity of our surfaces relies on a covalently
immobilized layer of IL-4, a key regulator of macro-
phage recruitment and anti-inﬂammatory polariza-
tion, to provide comprehensive suppression of
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General Conclusion 
The challenges of developing efficacious tissue engineering solutions are compounded by the 
requirements from the various fields of study which are incorporated into a single multi-disciplinary 
approach. Information from various areas of biology and medicine must successfully integrate with 
knowledge in materials synthesis and manufacturing in order to develop a tissue engineering solution 
that is both efficacious and translational. As a result, the field of tissue engineering has generated a 
limited number of clinical successes so far, and the future development of solutions is viewed as long 
and arduous. However, the outlook of the field is still bright given that advancements in technologies 
across the various stages of scaffold/construct development continue to progress. In particular, low-
throughput methodology in scaffold/construct development combined with a lack of consideration 
for their translational challenges continue to remain the limitations of tissue engineering solutions for 
clinical use in regenerative medicine. Developing the necessary tools to stream-line the 
scaffold/construct design process while incorporating strategies that utilize translationally relevant 
components have the potential to redefine numerous areas of the tissue engineering research field 
with significant implications for real-world regenerative medicine therapies. 
The findings of this thesis contribute novel solutions to the scaffold design problem by redefining the 
methodology through which scaffolds and constructs are fabricated. The utilization of the 
bioluminescence imaging modality has been a cornerstone to these studies by allowing for non-
invasive and real-time reporting of cellular behaviour both in vitro and in vivo. Incorporation of 
bioluminescence imaging can increase both the efficiency and accuracy of identifying optimal 
scaffolds and constructs for a given tissue engineering application. Cell responses toward scaffolds 
can be measured over time on a single scaffold, eliminating the need for multiple samples to account 
for time points along the cell growth curve. Additionally, by reporting real-time measurements, we 
are able to observe time-dependent changes in cellular behaviour, giving us more informed insight 
into the scaffold features which may enhance or impair cell function. This information helps to 
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eliminate the current methodology of trial-and-error fabrication by offering more suitable and 
accessible late-stage development testing.  
Tissue engineering product development conventionally starts with in vitro biological assays which 
then progress from small animal (rodent) models, large animal models and finally clinical trials in 
humans. While the great advantage of in vitro testing is that it allows a large degree of automation 
and high throughput screening of biomaterials, they are mostly limited to investigation at the cellular 
level and do not effectively mimic the complexity of tissue formation in vivo. Although more 
biologically and clinically relevant testing environments for biomaterial screening are implantation 
into the tissue itself, in vivo testing becomes generally expensive from excessive animal usage for 
evaluation at different time intervals, in addition to being time-consuming for histological analysis. 
These issues are more prevalent during the early phases of scaffold design where ideal cellular 
interactions with scaffold parameters are still unknown. While the use of bioluminescence imaging 
has revolutionized the field of stem cell biology, the potential benefits to the field of tissue 
engineering have not yet been fully explored, and the incorporation of bioluminescent reporters into 
tissue engineering strategies is still a recently developed concept. For example, bioluminescence 
reporters can be encoded into IL-1β promoter regions to more closely examine host inflammatory 
responses towards implanted scaffolds 121. The incorporation of bioluminescence imaging both in 
vitro and in vivo combined with endpoint molecular analysis techniques such as immunostaining 
and/or qPCR will enable the more rapid identification of scaffolds that exhibit the most favourable 
interaction with desired cell types for an intended tissue engineering application, greatly expediting 
the scaffold design process. 
Extending the functionality of this imaging approach will also undoubtedly allow for high-throughput 
investigations of scaffolds with novel cell types, paving the way for novel constructs with key 
translational features and high therapeutic potential. This concept is explored throughout this thesis 
with the investigation of the regenerative properties of iPSCs and their integration with tissue 
109 
 
engineering scaffolds. As previously discussed, one of the main translational challenges underlying 
stem-cell based tissue engineering and regenerative medicine approaches are stem cell sources 
capable of providing clinically relevant stem cell numbers. The advent of iPSC technology has 
revolutionised the stem cell biology field by providing an indefinite stem cell source that are void of 
the ethical concerns of previous approaches with embryonic stem cells. However, investigation of 
their numerous lineages and their respective regenerative properties are lacking, placing them merely 
as a potential stem cell source for tissue engineering. Developing iPSCs as a main stay element of the 
cellular component of the tissue engineering paradigm is a large endeavour requiring the investigation 
of multiple iPSC lineages. The investigation of iPSC-ECs in this thesis shows the tissue regeneration 
potential of this cell type, and more importantly, highlight their improved effectiveness when 
integrated with biomaterial scaffolds. These findings contribute to the notion that iPSCs may be the 
future cell source for tissue engineering constructs given their known translational qualities and 
recently growing demonstration of their regenerative effects. While the research field investigating 
iPSC laden tissue engineering constructs continues to expand, iPSC safety remains an ongoing issue 
preventing their clinical use in regenerative medicine. However, advances in iPSC technology are 
continually making them safer for use. For example, universal iPSC banking systems are currently 
being developed with genetically matched human leukocyte antigens (HLAs) which almost 
eliminates the likelihood of immune rejection and drastically improves their therapeutic potential. 
Additionally, while there is still no accepted method for large scale derivation and characterisation of 
iPSCs, numerous approaches have been reported focusing on reduced costs and high-throughput 
characterisation, which have been demonstrated to yield sizeable numbers of patient-specific iPSCs 
in clinically relevant time scales.  Given the rapidly approaching future of iPSC seeded scaffolds in 
tissue engineering, solutions improving the integration of these novel constructs with the body will 
be essential. Seamless integration of iPSC constructs has the potential of achieving some of tissue 
engineering’s largest outstanding goals, including the regeneration of whole organs and tissues.  
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To meet these demands, the large gap that exists within the tissue engineering field between research 
findings and translational applicability must first be bridged. The fundamental concepts of tissue 
engineered scaffolds to enhance stem cell survival and function have been widely demonstrated, 
however application of these strategies within the body presents another range of challenges. The 
longevity of any beneficial effect arising from these constructs are determined by the degree of host 
integration. Foreign body responses largely decide the success of any implanted construct or device.  
Although mitigating this host response to improve efficacy and safety is not a novel concept, current 
approaches employed typically rely on the view of the foreign body response as a binary biological 
process. Anti-inflammatory or anti-proliferative drugs are the most common approaches that aim to 
halt inflammation entirely through the inhibition of immune signalling or elimination immune cells, 
respectively. However, it is increasingly apparent that the immune response is a very dynamic 
response that facilitates numerous biological processes that may in fact assist in device integration. 
With this revamped perspective of the immune response, the studies within this thesis examine 
strategies that utilize, manipulate, and augment the body’s endogenous mechanisms to achieve more 
robust and long-lasting biological responses. This is exemplified in our bioactive coating 
functionalisation studies that target macrophage polarisation to facilitate a chain reaction of immune 
resolution. The demonstration of covalently immobilised monolayers of IL-4 represents the creation 
a biological barrier comprising of anti-inflammatory M2 macrophages that are resistant to chronic 
inflammation and instead enhance integration. Additionally, macrophages also participate in a host 
of tissue regeneration mechanisms in a variety of M2 sub-phenotypes. The ideal use of macrophage 
phenotype would be to first halt inflammation that is detrimental to implant acceptance of cell 
survival, while also simultaneously stimulating the body’s own capacity for tissue repair. Given their 
numerous roles and integral functions in many biological processes, the appropriate control over 
macrophages will only continue to grow as a central theme of tissue engineering solutions. However, 
having the appropriate control over the right functionalisation methods and biomolecules that are 
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capable of modulating macrophage phenotype will be equally crucial to the success of these future 
approaches.  
Scaffold functionalisation is an inevitable step in the fabrication process that is crucial to scaffold 
function, longevity, and safety. The incorporation of many growth factors, cytokines, drugs, and other 
biomolecules have been widely demonstrated with a wide range of beneficial effects. However, while 
these findings typically show promise within the confounds of research settings, the development of 
these approaches often fail to consider the translational requirements needed for clinical relevancy. 
The most notable of which being time, cost, and safety constraints of the manufacturing processes as 
previously discussed. The findings of this thesis largely address these considerations through the 
employment of PIII functionalisation methodology. As shown in our findings, PIII allows for robust 
immobilisation of biomolecules in clinically relevant time frames and this binding capacity possesses 
extended shelf-life, which opens up the translational possibilities of numerous tissue engineering 
solutions, while also potentially allowing for a revisit of the past research findings that have relied on 
the functionalisation of biomolecules but utilized non-translatable fabrication techniques. With the 
ongoing development and optimisation of these translational approaches, a change in the future 
landscape of the tissue engineering paradigm, in favour of solutions possessing more off-the-shelf 
versatility, may be imminent. When closely examining the paradigm, cellular components currently 
exhibit very low off-the-shelf properties due to the current lack of high-throughput derivation 
methods. With the availability of extended storage methods for biomolecules and non-degradable 
materials for scaffold manufacturing, these two components of the paradigm may instead highlight 
the future focus of the tissue engineering paradigm. Utilizing these two components, investigation of 
functionalisation technologies such as PIIII represents a method through which scaffolds can be 
functionalised with the necessary biomolecules with minimal preparation, prior to implantation in the 
body. These approaches hit upon the consistent themes of this thesis which are stimulating and 
enhancing innate biological processes through biomolecules, while also taking into consideration the 
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translational challenges that can hinder their development. Until there are advancements in the rapid 
derivation of stem cells and other cell sources, functionalised scaffolds pose as the most promising 
tissue engineering strategies with the highest likelihood of success in the short future. However, 
utilizing all components of the paradigm will still benefit research studies with crucial knowledge of 
the mechanisms underlying tissue repair and bring to light new strategies and targets which can 
augment these processes.  
Combining these essential research findings with clinically relevant development methods are 
represented as the cumulative findings of this thesis which impart both tools and lessons for the future 
development of translational biomaterials and tissue engineering solutions for regenerative medicine. 
The future of whole organ regeneration and functional restoration will undoubtedly lie in the form of 
combined research approaches incorporating the rapid identification of functional biomaterials, novel 
stem cell sources with enhance regenerative capacity, manipulation of the body’s innate biological 
mechanisms, and utilization of translational fabrication techniques. Incorporating the findings of 
these studies help to build the ongoing path towards accomplishing the outstanding goals of tissue 
engineering and regenerative medicine. With continued research, the allure of curing diseases once 
thought to be incurable comes even closer to reality. 
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